

**Clinical trial results:****A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer****Summary**

EudraCT number	2014-003208-59
Trial protocol	IT LV DE AT BE ES NL LT BG PT FR SK
Global end of trial date	17 February 2021

Results information

Result version number	v3 (current)
This version publication date	18 April 2022
First version publication date	13 October 2019
Version creation reason	

Trial information**Trial identification**

Sponsor protocol code	GO29437
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02367794
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 February 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	17 February 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of this randomized, Phase III, multicenter, open-label study was to evaluate the safety and efficacy of atezolizumab in combination with carboplatin + paclitaxel or with carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in approximately 1025 chemotherapy-naïve patients with Stage IV squamous non-small cell lung cancer (NSCLC).

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 June 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 12
Country: Number of subjects enrolled	Australia: 33
Country: Number of subjects enrolled	Austria: 3
Country: Number of subjects enrolled	Belgium: 16
Country: Number of subjects enrolled	Bulgaria: 9
Country: Number of subjects enrolled	Brazil: 27
Country: Number of subjects enrolled	Canada: 16
Country: Number of subjects enrolled	Chile: 20
Country: Number of subjects enrolled	Germany: 72
Country: Number of subjects enrolled	Spain: 142
Country: Number of subjects enrolled	France: 35
Country: Number of subjects enrolled	Israel: 21
Country: Number of subjects enrolled	Italy: 37
Country: Number of subjects enrolled	Japan: 83
Country: Number of subjects enrolled	Lithuania: 1
Country: Number of subjects enrolled	Latvia: 12
Country: Number of subjects enrolled	Mexico: 4
Country: Number of subjects enrolled	Netherlands: 16
Country: Number of subjects enrolled	Peru: 6
Country: Number of subjects enrolled	Portugal: 12

Country: Number of subjects enrolled	Russian Federation: 35
Country: Number of subjects enrolled	Singapore: 12
Country: Number of subjects enrolled	Slovakia: 6
Country: Number of subjects enrolled	Taiwan: 12
Country: Number of subjects enrolled	Ukraine: 178
Country: Number of subjects enrolled	United States: 201
Worldwide total number of subjects	1021
EEA total number of subjects	361

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	476
From 65 to 84 years	543
85 years and over	2

Subject disposition

Recruitment

Recruitment details:

'Study Terminated By Sponsor' Reason for Not Completed is a data entry error; reason for not completed is unknown. The study was Completed and not Terminated.

Pre-assignment

Screening details:

Participants in this study included chemotherapy-naïve patients with Stage IV squamous non-small cell lung cancer (NSCLC).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm C: Nab-Paclitaxel + Carboplatin

Arm description:

The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care.

Arm type	Active comparator
Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.

Investigational medicinal product name	Nab-Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Nab-paclitaxel 100 milligrams per meter squared (mg/m²) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.

Arm title	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
------------------	--

Arm description:

The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	Tecentriq
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.

Investigational medicinal product name	Nab-Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Nab-paclitaxel 100 milligrams per meter squared (mg/m²) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.

Arm title	Arm A: Atezolizumab + Paclitaxel + Carboplatin
------------------	--

Arm description:

The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.

Arm type	Experimental
Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	Tecentriq
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Paclitaxel 200 mg/m² IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m² IV.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute

(mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.

Number of subjects in period 1	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin
Started	340	343	338
Completed	0	0	0
Not completed	340	343	338
Adverse event, serious fatal	252	245	243
Randomized in error	-	-	1
Physician decision	-	5	3
Discontinuation Matched Treatment Discontinuation	-	-	1
Patient unable to receive carboplatin	-	-	1
Investigational Product in Commercial Stock	-	1	-
Moved to Commercial Atezolizumab Use	-	2	1
Brain metastasis	1	-	-
Consent withdrawn by subject	25	12	20
Moved to Roll-Over Study	-	15	13
Study Terminated By Sponsor	-	1	1
Adverse event, non-fatal	-	-	2
Participant Enrolled in Extended Protocol	-	1	-
Lost to follow-up	1	2	2
Sponsor Request	60	57	45
Moved into PTAP Study	-	2	3
Protocol deviation	1	-	1
Hypercalcemia prior to C1D1	-	-	1

Baseline characteristics

Reporting groups

Reporting group title	Arm C: Nab-Paclitaxel + Carboplatin
-----------------------	-------------------------------------

Reporting group description:

The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care.

Reporting group title	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
-----------------------	--

Reporting group description:

The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.

Reporting group title	Arm A: Atezolizumab + Paclitaxel + Carboplatin
-----------------------	--

Reporting group description:

The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.

Reporting group values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects	340	343	338
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	156	170	150
From 65-84 years	183	173	187
85 years and over	1	0	1
Age Continuous Units: Years			
arithmetic mean	64.9	64.0	65.0
standard deviation	± 8.1	± 9.2	± 8.3
Sex: Female, Male Units: Participants			
Female	63	63	60
Male	277	280	278

Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	24	27	28
Not Hispanic or Latino	299	306	297
Unknown or Not Reported	17	10	13
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	1	1	3
Asian	37	41	34
Native Hawaiian or Other Pacific Islander	0	0	1
Black or African American	7	4	3
White	290	289	290
More than one race	1	6	1
Unknown or Not Reported	4	2	6

Reporting group values	Total		
Number of subjects	1021		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	476		
From 65-84 years	543		
85 years and over	2		
Age Continuous			
Units: Years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: Participants			
Female	186		
Male	835		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	79		
Not Hispanic or Latino	902		
Unknown or Not Reported	40		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	5		
Asian	112		
Native Hawaiian or Other Pacific Islander	1		
Black or African American	14		
White	869		
More than one race	8		

Unknown or Not Reported	12		
-------------------------	----	--	--

End points

End points reporting groups

Reporting group title	Arm C: Nab-Paclitaxel + Carboplatin
Reporting group description: The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care.	
Reporting group title	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Reporting group description: The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.	
Reporting group title	Arm A: Atezolizumab + Paclitaxel + Carboplatin
Reporting group description: The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.	

Primary: Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population

End point title	Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population
End point description: PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.	
End point type	Primary
End point timeframe: Up to approximately 30 months after first participant enrolled	

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	340	343	338	
Units: Months				
median (confidence interval 95%)	5.6 (5.5 to 5.7)	6.5 (5.7 to 7.1)	5.6 (5.5 to 6.9)	

Statistical analyses

Statistical analysis title	PFS in ITT
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	683
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0006
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.64
upper limit	0.88

Primary: Overall Survival (OS) in the ITT Population

End point title	Overall Survival (OS) in the ITT Population
End point description:	
OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.	
End point type	Primary
End point timeframe:	
Up to approximately 39 months after first participant enrolled	

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	340	343	338	
Units: Months				
median (confidence interval 95%)	13.5 (12.2 to 15.1)	14.2 (12.3 to 16.8)	12.6 (11.6 to 14.7)	

Statistical analyses

Statistical analysis title	OS in ITT
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	683
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1581
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	1.05

Secondary: PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population

End point title	PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population
End point description:	PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population.
End point type	Secondary
End point timeframe:	Up to approximately 30 months after first participant enrolled

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	108	115	100	
Units: Months				
median (confidence interval 95%)	5.6 (5.1 to 5.7)	8.4 (6.8 to 10.4)	7.0 (5.6 to 8.3)	

Statistical analyses

Statistical analysis title	PFS in TC 2/3 or IC 2/3 Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin

Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	0.72

Statistical analysis title	PFS in TC 2/3 or IC 2/3 Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	208
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0018
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	0.84

Secondary: PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population

End point title	PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population
End point description:	PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the TC1/2/3 or IC1/2/3 Population.
End point type	Secondary
End point timeframe:	Up to approximately 30 months after first participant enrolled

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	169	182	167	
Units: Months				
median (confidence interval 95%)	5.6 (5.3 to 5.7)	7.1 (5.8 to 8.3)	7.0 (5.6 to 8.3)	

Statistical analyses

Statistical analysis title	PFS in TC 1/2/3 or IC 1/2/3 Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	336
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	0.77

Statistical analysis title	PFS in TC 1/2/3 or IC 1/2/3 Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	0.77

Secondary: OS in the TC2/3 or IC2/3 Population

End point title	OS in the TC2/3 or IC2/3 Population
-----------------	-------------------------------------

End point description:

OS is defined as the time between the date of randomization and date of death from any cause, in the TC2/3 or IC2/3 Population.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 39 months after first participant enrolled

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	108	115	100	
Units: Months				
median (confidence interval 95%)	14.5 (12.1 to 17.2)	20.4 (13.8 to 24.1)	14.8 (11.1 to 23.7)	

Statistical analyses

Statistical analysis title	OS in TC 2/3 or IC 2/3 Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	208
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0518
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.725
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.524
upper limit	1.004

Statistical analysis title	OS in TC 2/3 or IC 2/3 Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	223
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2841
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.832

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.594
upper limit	1.165

Secondary: OS in the TC1/2/3 or IC1/2/3 Population

End point title	OS in the TC1/2/3 or IC1/2/3 Population
End point description:	
OS is defined as the time between the date of randomization and date of death from any cause in the TC1/2/3 or IC1/2/3 Population.	
End point type	Secondary
End point timeframe:	
Up to approximately 39 months after first participant enrolled	

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	169	182	167	
Units: Months				
median (confidence interval 95%)	15.0 (12.4 to 17.2)	14.8 (12.1 to 19.6)	14.9 (12.5 to 18.2)	

Statistical analyses

Statistical analysis title	OS in TC 1/2/3 or IC 1/2/3 Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	351
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2473
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.861
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.668
upper limit	1.109

Statistical analysis title	OS in TC 1/2/3 or IC 1/2/3 Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	336
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2956
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.871
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.671
upper limit	1.129

Secondary: Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population

End point title	Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population
End point description:	Proportion of participants with an objective response (CR or PR) in the ITT population.
End point type	Secondary
End point timeframe:	Up to approximately 30 months after first participant enrolled

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	339	342	337	
Units: Percentage of participants				
number (not applicable)	41.0	49.7	49.3	

Statistical analyses

Statistical analysis title	OR in ITT Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin

Number of subjects included in analysis	681
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0248
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	1.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.04
upper limit	1.91

Statistical analysis title	OR in ITT Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	676
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0308
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.03
upper limit	1.9

Secondary: Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population

End point title	Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population
End point description:	Duration of response is defined as the time from the first documented objective response to documented PD or death from any cause, whichever occurred first, in the ITT Population.
End point type	Secondary
End point timeframe:	Up to approximately 30 months after first participant enrolled

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	139	170	166	
Units: Months				
median (confidence interval 95%)	5.2 (4.4 to 5.6)	7.2 (6.8 to 9.5)	7.0 (5.7 to 8.3)	

Statistical analyses

Statistical analysis title	DOR in ITT Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	305
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0007
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.493
upper limit	0.831

Statistical analysis title	DOR in ITT Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	309
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.408
upper limit	0.689

Secondary: Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population

End point title	Time to Deterioration (TTD) in Patient-reported Lung Cancer
-----------------	---

End point description:

TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population. The EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC scales and single-item measures will be linearly transformed so that each score has a range of 0-100. A high score for a functional scale represents a high or healthy level of functioning, and a high score for the global health status and HRQoL represents a high HRQoL; however, a high score for a symptom scale or item represents a high level of symptomatology or problems.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 30 months after first participant enrolled

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	340	343	338	
Units: Months				
median (confidence interval 95%)	3.2 (2.6 to 4.1)	4.2 (3.2 to 5.6)	3.0 (2.6 to 3.9)	

Statistical analyses

Statistical analysis title	TTD Using EORTC QLQ-C30 in ITT Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	678
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.7295
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.834
upper limit	1.296

Statistical analysis title	TTD Using EORTC QLQ-C30 in ITT Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin

Number of subjects included in analysis	683
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0461
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.797
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.638
upper limit	0.996

Secondary: TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population

End point title	TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population
-----------------	---

End point description:

TTD was documented for a 3-symptom composite endpoint using the following EORTC QLQ-LC13 symptom scores: cough, chest pain, and dyspnea multi-item scale. In this instance, symptom deterioration will be determined as a ≥ 10 -point increase above baseline in any of the listed symptom scores, whichever occurs first (cough, chest pain, and dyspnea multi-item scale). Confirmed clinically meaningful symptom deterioration will need to be held for the original symptom; a ≥ 10 -point increase above baseline in a symptom score must be held for at least two consecutive assessments or an initial ≥ 10 -point increase above baseline followed by death within 3 weeks from the last assessment. A ≥ 10 -point change in the EORTC scale score is perceived by patients as clinically significant.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 30 months after the first participant enrolled

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	340	343	338	
Units: Months				
median (confidence interval 95%)	2.6 (2.2 to 3.0)	3.4 (2.7 to 5.1)	2.8 (2.1 to 3.7)	

Statistical analyses

Statistical analysis title	TTD Using EORTC QLQ-LC13 in ITT Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin

Number of subjects included in analysis	678
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.7692
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.968
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.779
upper limit	1.203

Statistical analysis title	TTD Using EORTC QLQ-LC13 in ITT Population
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	683
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0906
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.828
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.666
upper limit	1.031

Secondary: Change from Baseline in Patient-reported Lung Cancer Symptoms Score using the SILC Scale Symptom Severity Score in the ITT Population

End point title	Change from Baseline in Patient-reported Lung Cancer Symptoms Score using the SILC Scale Symptom Severity Score in the ITT Population
-----------------	---

End point description:

Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥ 0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of ≥ 0.5 points for chest pain score is considered to be clinically significant. (Note: PD=progression of disease. FU=follow up. Note: 999999=not available.)

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to approximately 30 months after first participant enrolled

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	189	215	195	
Units: Units on a scale				
arithmetic mean (standard deviation)				
Chest Pain, Week 1 (n=171, 192,166)	0.04 (± 0.93)	0.14 (± 0.87)	0.44 (± 1.03)	
Chest Pain, Week 2 (n=160, 186, 165)	-0.08 (± 0.89)	0.09 (± 0.98)	0.28 (± 1.00)	
Chest Pain, Week 3 (n=165, 175, 165)	-0.14 (± 0.95)	-0.03 (± 0.78)	-0.05 (± 1.00)	
Chest Pain, Week 4 (n=157, 173, 169)	-0.19 (± 0.98)	-0.05 (± 0.98)	0.09 (± 1.12)	
Chest Pain, Week 5 (n=160, 172, 159)	-0.17 (± 1.10)	-0.08 (± 0.99)	-0.16 (± 1.09)	
Chest Pain, Week 6 (n=151, 170, 161)	-0.35 (± 1.08)	-0.13 (± 0.99)	-0.20 (± 1.02)	
Chest Pain, Week 7 (n=138, 166, 143)	-0.38 (± 1.12)	-0.18 (± 0.92)	-0.14 (± 1.16)	
Chest Pain, Week 8 (n=140, 162, 152)	-0.35 (± 1.12)	-0.17 (± 1.02)	-0.17 (± 1.09)	
Chest Pain, Week 9 (n=135, 162, 143)	-0.36 (± 1.00)	-0.19 (± 0.97)	-0.21 (± 1.10)	
Chest Pain, Week 10 (n=133, 158, 146)	-0.20 (± 1.09)	-0.16 (± 1.00)	-0.08 (± 1.19)	
Chest Pain, Week 11 (n=132, 157, 137)	-0.27 (± 1.08)	-0.24 (± 0.91)	-0.09 (± 1.16)	
Chest Pain, Week 12 (n=128, 151, 136)	-0.34 (± 1.05)	-0.21 (± 1.01)	-0.30 (± 1.05)	
Chest Pain, Week 13 (n=117, 144, 130)	-0.31 (± 1.24)	-0.22 (± 1.02)	-0.17 (± 1.10)	
Chest Pain, Week 14 (n=105, 139, 138)	-0.32 (± 1.18)	-0.24 (± 0.88)	-0.15 (± 1.13)	
Chest Pain, Week 15 (n=97, 143, 132)	-0.45 (± 1.19)	-0.28 (± 0.99)	-0.17 (± 1.00)	
Chest Pain, Week 16 (n=102, 138, 121)	-0.28 (± 1.10)	-0.14 (± 1.00)	-0.23 (± 1.10)	
Chest Pain, Week 17 (n=101, 135, 129)	-0.32 (± 1.11)	-0.17 (± 0.99)	-0.24 (± 1.10)	
Chest Pain, Week 18 (n=93, 141, 129)	-0.28 (± 1.08)	-0.13 (± 0.99)	-0.17 (± 1.09)	
Chest Pain, Week 19 (n=85, 129, 118)	-0.18 (± 1.09)	-0.10 (± 0.99)	-0.16 (± 1.07)	
Chest Pain, Week 20 (n=75, 130, 114)	-0.23 (± 1.07)	-0.15 (± 0.94)	-0.17 (± 1.13)	
Chest Pain, Week 21 (n=69, 129, 113)	-0.37 (± 1.02)	-0.07 (± 1.02)	-0.18 (± 1.14)	
Chest Pain, Week 22 (n=79, 125, 109)	-0.27 (± 1.18)	-0.08 (± 1.01)	-0.14 (± 1.16)	
Chest Pain, Week 23 (n=70, 128, 106)	-0.29 (± 1.16)	0.04 (± 0.96)	-0.10 (± 1.07)	
Chest Pain, Week 24 (n=67, 121, 105)	-0.43 (± 1.15)	-0.15 (± 0.97)	-0.17 (± 1.14)	
Chest Pain, Week 25 (n=48, 118, 104)	-0.25 (± 1.24)	-0.17 (± 1.06)	-0.20 (± 1.10)	
Chest Pain, Week 26 (n=48, 111, 99)	-0.50 (± 1.20)	-0.06 (± 1.08)	-0.11 (± 1.09)	
Chest Pain, Week 27 (n=42, 110, 95)	-0.35 (± 1.29)	-0.17 (± 1.03)	0.04 (± 1.14)	
Chest Pain, Week 28 (n=41, 103, 88)	-0.22 (± 1.27)	-0.12 (± 1.09)	-0.19 (± 1.24)	
Chest Pain, Week 29 (n=38, 100, 89)	-0.30 (± 1.23)	-0.11 (± 0.96)	-0.18 (± 1.11)	
Chest Pain, Week 30 (n=46, 104, 86)	-0.15 (± 1.36)	-0.21 (± 1.02)	-0.08 (± 1.09)	
Chest Pain, Week 31 (n=35, 97, 77)	-0.49 (± 1.25)	-0.16 (± 0.99)	-0.15 (± 1.08)	
Chest Pain, Week 32 (n=29, 91, 70)	-0.29 (± 1.16)	-0.15 (± 0.88)	-0.16 (± 1.01)	
Chest Pain, Week 33 (n=29, 93, 68)	-0.29 (± 1.35)	-0.20 (± 0.97)	-0.10 (± 1.09)	
Chest Pain, Week 34 (n=33, 92, 73)	-0.15 (± 1.42)	-0.04 (± 0.89)	0.02 (± 1.16)	
Chest Pain, Week 35 (n=33, 90, 72)	-0.26 (± 1.31)	-0.14 (± 0.88)	-0.19 (± 1.09)	
Chest Pain, Week 36 (n=31, 83, 64)	-0.24 (± 1.34)	-0.06 (± 0.88)	-0.06 (± 1.12)	
Chest Pain, Week 37 (n=24, 84, 65)	-0.27 (± 1.37)	0.05 (± 1.06)	-0.08 (± 1.08)	
Chest Pain, Week 38 (n=24, 86, 65)	-0.19 (± 1.30)	-0.09 (± 0.97)	-0.14 (± 1.13)	
Chest Pain, Week 39 (n=25, 75, 68)	-0.06 (± 1.53)	-0.18 (± 0.96)	-0.13 (± 1.13)	
Chest Pain, Week 40 (n=24, 74, 62)	0.06 (± 1.31)	-0.11 (± 0.85)	-0.06 (± 1.01)	
Chest Pain, Week 41 (n=22, 69, 60)	0.14 (± 1.21)	-0.14 (± 0.92)	-0.13 (± 1.05)	

Chest Pain, Week 42 (n=24, 77, 60)	-0.10 (± 1.50)	-0.05 (± 0.94)	-0.11 (± 1.02)
Chest Pain, Week 43 (n=23, 72, 58)	0.13 (± 1.59)	-0.08 (± 0.99)	0.05 (± 1.13)
Chest Pain, Week 44 (n=20, 93, 60)	-0.08 (± 1.52)	-0.25 (± 0.99)	-0.10 (± 1.07)
Chest Pain, Week 45 (n=20, 64, 51)	0.15 (± 1.70)	-0.21 (± 0.97)	-0.05 (± 1.20)
Chest Pain, Week 46 (n=20, 61, 53)	0.00 (± 1.39)	-0.16 (± 1.04)	-0.07 (± 1.33)
Chest Pain, Week 47 (n=20, 64, 48)	0.18 (± 1.29)	-0.16 (± 0.99)	0.04 (± 1.29)
Chest Pain, Week 48 (n=19, 62, 52)	-0.08 (± 1.53)	-0.17 (± 0.97)	0.00 (± 1.32)
Chest Pain, Week 49 (n=13, 57, 45)	-0.23 (± 1.59)	-0.24 (± 1.05)	-0.09 (± 1.31)
Chest Pain, Week 50 (n=15, 60, 45)	0.00 (± 1.73)	-0.17 (± 0.98)	-0.14 (± 1.36)
Chest Pain, Week 51 (n=11, 58, 37)	0.55 (± 1.39)	-0.16 (± 1.07)	-0.19 (± 1.24)
Chest Pain, Week 52 (n=13, 58, 43)	0.15 (± 1.30)	-0.09 (± 0.98)	0.02 (± 1.30)
Chest Pain, Week 53 (n=14, 53, 35)	0.18 (± 1.27)	-0.12 (± 0.95)	-0.20 (± 1.22)
Chest Pain, Week 54 (n=13, 56, 36)	0.08 (± 1.17)	-0.18 (± 0.92)	-0.24 (± 1.34)
Chest Pain, Week 55 (n=12, 47, 36)	0.21 (± 1.37)	-0.11 (± 0.79)	-0.15 (± 1.19)
Chest Pain, Week 56 (n=11, 50, 36)	0.05 (± 1.39)	-0.22 (± 0.91)	-0.08 (± 1.36)
Chest Pain, Week 57 (n=10, 52, 33)	0.05 (± 1.46)	-0.22 (± 0.95)	-0.27 (± 1.22)
Chest Pain, Week 58 (n=8, 45, 29)	0.13 (± 1.25)	-0.22 (± 0.86)	-0.24 (± 1.12)
Chest Pain, Week 59 (n=11, 47, 27)	0.00 (± 1.32)	-0.20 (± 1.01)	-0.28 (± 1.17)
Chest Pain, Week 60 (n=11, 41, 31)	0.09 (± 1.59)	-0.27 (± 0.97)	-0.26 (± 1.22)
Chest Pain, Week 61 (n=9, 40, 28)	0.61 (± 1.29)	-0.23 (± 0.83)	-0.34 (± 1.23)
Chest Pain, Week 62 (n=10, 39, 25)	0.05 (± 1.34)	-0.03 (± 1.00)	-0.36 (± 0.96)
Chest Pain, Week 63 (n=8, 42, 22)	-0.44 (± 1.21)	-0.12 (± 0.92)	-0.55 (± 1.13)
Chest Pain, Week 64 (n=8, 42, 18)	0.19 (± 1.49)	-0.13 (± 0.99)	-0.42 (± 1.33)
Chest Pain, Week 65 (n=6, 39, 20)	0.25 (± 1.37)	-0.13 (± 0.95)	-0.25 (± 1.21)
Chest Pain, Week 66 (n=6, 37, 19)	0.42 (± 1.53)	0.00 (± 1.26)	-0.47 (± 1.18)
Chest Pain, Week 67 (n=5, 33, 20)	-0.50 (± 1.27)	-0.08 (± 1.04)	-0.43 (± 1.27)
Chest Pain, Week 68 (n=6, 33, 19)	0.08 (± 1.77)	-0.09 (± 1.02)	-0.53 (± 1.23)
Chest Pain, Week 69 (n=5, 31, 18)	0.70 (± 1.60)	-0.15 (± 1.08)	-0.03 (± 1.14)
Chest Pain, Week 70 (n=5, 32, 19)	0.30 (± 1.79)	-0.06 (± 0.97)	-0.32 (± 1.08)
Chest Pain, Week 71 (n=6, 27, 15)	0.08 (± 1.72)	-0.13 (± 0.91)	-0.43 (± 1.22)
Chest Pain, Week 72 (n=6, 27, 18)	0.25 (± 1.70)	-0.20 (± 0.94)	-0.14 (± 1.00)
Chest Pain, Week 73 (n=6, 27, 13)	0.42 (± 1.53)	-0.02 (± 1.09)	-0.08 (± 1.27)
Chest Pain, Week 74 (n=7, 29, 12)	0.43 (± 1.62)	-0.10 (± 1.14)	-0.38 (± 1.21)
Chest Pain, Week 75 (n=6, 24, 12)	0.25 (± 1.70)	-0.17 (± 0.89)	-0.21 (± 1.18)
Chest Pain, Week 76 (n=6, 23, 14)	0.00 (± 1.76)	-0.02 (± 1.03)	-0.21 (± 1.25)
Chest Pain, Week 77 (n=6, 22, 10)	0.00 (± 1.76)	0.00 (± 1.15)	-0.05 (± 1.21)
Chest Pain, Week 78 (n=7, 22, 11)	0.07 (± 1.62)	-0.11 (± 1.11)	0.00 (± 1.02)
Chest Pain, Week 79 (n=6, 24, 9)	0.08 (± 1.72)	-0.13 (± 0.86)	0.17 (± 0.94)
Chest Pain, Week 80 (n=7, 20, 11)	0.14 (± 1.65)	-0.35 (± 0.99)	0.09 (± 1.14)
Chest Pain, Week 81 (n=6, 18, 9)	0.25 (± 1.70)	-0.25 (± 0.90)	0.22 (± 0.97)
Chest Pain, Week 82 (n=7, 21, 9)	0.07 (± 1.62)	-0.31 (± 1.03)	0.22 (± 1.12)
Chest Pain, Week 83 (n=5, 19, 10)	0.00 (± 1.77)	-0.32 (± 1.03)	-0.05 (± 1.01)
Chest Pain, Week 84 (n=5, 15, 10)	0.00 (± 1.84)	-0.33 (± 1.08)	0.35 (± 1.00)
Chest Pain, Week 85 (n=4, 17, 10)	1.13 (± 1.31)	-0.35 (± 1.03)	0.30 (± 1.14)
Chest Pain, Week 86 (n=3, 15, 6)	1.33 (± 1.53)	-0.37 (± 0.95)	0.33 (± 1.37)
Chest Pain, Week 87 (n=3, 12, 8)	1.00 (± 1.73)	-0.25 (± 1.10)	0.13 (± 0.99)
Chest Pain, Week 88 (n=3, 15, 7)	0.83 (± 1.44)	-0.20 (± 1.22)	0.00 (± 1.00)
Chest Pain, Week 89 (n=3, 14, 7)	0.67 (± 2.08)	-0.14 (± 1.08)	-0.29 (± 1.25)
Chest Pain, Week 90 (n=3, 13, 7)	0.67 (± 2.08)	-0.04 (± 1.25)	0.00 (± 1.29)
Chest Pain, Week 91 (n=3, 13, 7)	1.17 (± 1.61)	-0.42 (± 1.13)	0.14 (± 1.07)
Chest Pain, Week 92 (n=4, 13, 8)	0.88 (± 1.44)	-0.15 (± 1.20)	0.19 (± 1.25)
Chest Pain, Week 93 (n=2, 13, 10)	1.50 (± 2.12)	0.00 (± 1.24)	-0.05 (± 1.01)

Chest Pain, Week 94 (n=3, 11, 8)	0.67 (± 2.08)	-0.23 (± 1.35)	0.00 (± 1.20)
Chest Pain, Week 95 (n=3, 11, 8)	0.67 (± 2.08)	0.14 (± 1.19)	0.25 (± 1.00)
Chest Pain, Week 96 (n=3, 11, 8)	1.17 (± 1.61)	0.09 (± 1.53)	0.19 (± 0.92)
Chest Pain, Week 97 (n=3, 11, 9)	1.17 (± 1.61)	-0.18 (± 1.54)	-0.11 (± 1.17)
Chest Pain, Week 98 (n=3, 10, 7)	0.83 (± 2.02)	0.05 (± 1.48)	0.00 (± 1.00)
Chest Pain, Week 99 (n=3, 10, 7)	0.67 (± 2.08)	0.00 (± 1.53)	0.07 (± 1.02)
Chest Pain, Week 100 (n=2, 10, 8)	1.25 (± 1.77)	-0.15 (± 1.43)	0.00 (± 1.20)
Chest Pain, Week 101 (n=3, 10, 7)	1.17 (± 1.61)	-0.10 (± 1.54)	0.21 (± 0.99)
Chest Pain, Week 102 (n=3, 6, 6)	1.00 (± 1.32)	-0.25 (± 0.88)	0.08 (± 1.11)
Chest Pain, Week 103 (n=2, 9, 6)	-0.50 (± 0.71)	-0.56 (± 1.04)	0.17 (± 1.17)
Chest Pain, Week 104 (n=2, 8, 4)	0.25 (± 0.35)	-0.56 (± 1.05)	0.00 (± 1.41)
Chest Pain, Week 105 (n=2, 6, 6)	0.50 (± 0.00)	-0.50 (± 0.84)	0.00 (± 1.10)
Chest Pain, Week 106 (n=2, 9, 5)	0.00 (± 0.00)	-0.72 (± 1.06)	-0.40 (± 1.14)
Chest Pain, Week 107 (n=2, 7, 4)	0.25 (± 0.35)	-0.57 (± 1.17)	-0.50 (± 0.58)
Chest Pain, Week 108 (n=2, 5, 4)	0.25 (± 0.35)	-0.30 (± 1.25)	-0.38 (± 0.75)
Chest Pain, Week 109 (n=2, 5, 2)	-0.50 (± 0.71)	-0.90 (± 1.24)	0.25 (± 1.77)
Chest Pain, Week 110 (n=2, 3, 4)	0.00 (± 0.71)	-0.50 (± 1.32)	-0.38 (± 1.11)
Chest Pain, Week 111 (n=2, 4, 4)	0.25 (± 0.35)	-0.25 (± 1.26)	-0.38 (± 0.48)
Chest Pain, Week 112 (n=2, 3, 2)	0.50 (± 0.00)	-0.67 (± 1.15)	-1.00 (± 0.00)
Chest Pain, Week 113 (n=1, 4, 3)	0.00 (± 999999)	-0.50 (± 1.00)	-0.67 (± 0.58)
Chest Pain, Week 114 (n=2, 3, 2)	-0.25 (± 1.06)	-0.50 (± 1.32)	-1.00 (± 0.00)
Chest Pain, Week 115 (n=2, 4, 3)	-0.25 (± 1.06)	-0.50 (± 1.00)	-0.67 (± 0.58)
Chest Pain, Week 116 (n=2, 3, 3)	-0.50 (± 0.71)	-0.67 (± 1.15)	-0.67 (± 0.58)
Chest Pain, Week 117 (n=2, 2, 2)	-0.25 (± 1.06)	-1.00 (± 1.41)	-1.00 (± 0.00)
Chest Pain, Week 118 (n=1, 1, 2)	0.00 (± 999999)	0.00 (± 999999)	-1.00 (± 0.00)
Chest Pain, Week 119 (n=0, 1, 2)	999999 (± 999999)	0.00 (± 999999)	-1.00 (± 0.00)
Chest Pain, Week 120 (n=0, 1, 2)	999999 (± 999999)	0.00 (± 999999)	-1.00 (± 0.00)
Chest Pain, Week 121 (n=0, 1, 2)	999999 (± 999999)	0.00 (± 999999)	-1.00 (± 0.00)
Chest Pain, Week 122 (n=0, 1, 2)	999999 (± 999999)	0.00 (± 999999)	-1.00 (± 0.00)
Chest Pain, Week 123 (n=0, 1, 1)	999999 (± 999999)	0.00 (± 999999)	-1.00 (± 999999)
Chest Pain, Week 124 (n=0, 1, 1)	999999 (± 999999)	0.00 (± 999999)	-0.50 (± 999999)
Chest Pain, Week 125 (n=0, 0, 1)	999999 (± 999999)	999999 (± 999999)	-0.50 (± 999999)
Chest Pain, Week 126 (n=0, 0, 1)	999999 (± 999999)	999999 (± 999999)	-0.50 (± 999999)
Chest Pain, Week 127 (n=0, 0, 1)	999999 (± 999999)	999999 (± 999999)	-1.00 (± 999999)
Chest Pain, Time of First Pd (n=103, 107, 106)	-0.19 (± 1.13)	0.10 (± 1.12)	-0.11 (± 1.21)
Chest Pain, Time of Last Tx Dose (n=161, 172, 151)	-0.18 (± 1.06)	0.01 (± 1.09)	0.05 (± 1.14)
Chest Pain, Survival FU Month 1 (n=86, 0, 0)	0.03 (± 1.30)	-0.10 (± 1.03)	-0.08 (± 0.95)
Chest Pain, Survival FU Month 2 (n=52, 0, 0)	-0.10 (± 1.23)	-0.16 (± 1.04)	-0.33 (± 1.07)
Chest Pain, Survival FU Month 3 (n=40, 0, 0)	-0.09 (± 1.13)	-0.24 (± 1.08)	-0.19 (± 1.13)
Chest Pain, Survival FU Month 4 (n=32, 0, 0)	-0.13 (± 1.15)	-0.22 (± 1.01)	-0.35 (± 1.11)

Chest Pain, Survival FU Month 5 (n=26, 0, 0)	-0.02 (± 1.34)	-0.27 (± 1.07)	-0.47 (± 1.11)
Chest Pain, Survival FU Month 6 (n=23, 0, 0)	-0.22 (± 0.99)	-0.26 (± 0.97)	-0.36 (± 1.09)
Chest Pain, Survival FU Month 7 (n=3, 0, 0)	0.33 (± 0.58)	-0.27 (± 1.01)	-0.34 (± 1.09)
Chest Pain, Survival FU Month 8 (n=2, 0, 0)	-0.75 (± 1.06)	-0.28 (± 1.09)	-0.42 (± 1.08)
Cough, Week 1 (n=171, 192, 166)	0.01 (± 0.78)	0.03 (± 0.82)	-0.02 (± 0.74)
Cough, Week 2 (n=160, 186, 165)	-0.02 (± 0.91)	0.00 (± 0.90)	0.17 (± 0.87)
Cough, Week 3 (n=165, 175, 165)	-0.09 (± 0.90)	-0.10 (± 1.03)	-0.08 (± 0.95)
Cough, Week 4 (n=157, 173, 169)	-0.26 (± 0.92)	-0.16 (± 1.04)	-0.33 (± 1.07)
Cough, Week 5 (n=160, 172, 159)	-0.18 (± 1.02)	-0.24 (± 1.08)	-0.19 (± 1.13)
Cough, Week 6 (n=151, 170, 161)	-0.27 (± 1.05)	-0.22 (± 1.01)	-0.35 (± 1.11)
Cough, Week 7 (n=138, 166, 143)	-0.27 (± 1.06)	-0.27 (± 1.07)	-0.47 (± 1.11)
Cough, Week 8 (n=140, 162, 152)	-0.26 (± 1.11)	-0.26 (± 0.97)	-0.36 (± 1.09)
Cough, Week 9 (n=135, 162, 143)	-0.32 (± 1.16)	-0.27 (± 1.01)	-0.34 (± 1.09)
Cough, Week 10 (n=133, 158, 146)	-0.28 (± 1.02)	-0.28 (± 1.09)	-0.42 (± 1.08)
Cough, Week 11 (n=132, 157, 137)	-0.31 (± 0.98)	-0.27 (± 1.14)	-0.50 (± 1.06)
Cough, Week 12 (n=128, 151, 136)	-0.30 (± 1.08)	-0.25 (± 1.13)	-0.46 (± 1.06)
Cough, Week 13 (n=117, 144, 130)	-0.23 (± 1.14)	-0.28 (± 1.17)	-0.46 (± 1.10)
Cough, Week 14 (n=105, 139, 138)	-0.31 (± 1.09)	-0.29 (± 1.13)	-0.50 (± 1.16)
Cough, Week 15 (n=97, 143, 132)	-0.39 (± 1.11)	-0.23 (± 1.03)	-0.47 (± 1.18)
Cough, Week 16 (n=102, 138, 121)	-0.19 (± 1.19)	-0.18 (± 1.14)	-0.52 (± 1.25)
Cough, Week 17 (n=101, 135, 129)	-0.18 (± 1.08)	-0.21 (± 1.06)	-0.48 (± 1.16)
Cough, Week 18 (n=93, 141, 129)	-0.26 (± 1.09)	-0.34 (± 1.12)	-0.48 (± 1.05)
Cough, Week 19 (n=85, 129, 118)	-0.29 (± 1.05)	-0.29 (± 1.12)	-0.37 (± 1.04)
Cough, Week 20 (n=75, 130, 114)	-0.29 (± 1.09)	-0.24 (± 1.00)	-0.51 (± 1.15)
Cough, Week 21 (n=69, 129, 113)	-0.36 (± 1.01)	-0.26 (± 1.06)	-0.46 (± 1.09)
Cough, Week 22 (n=79, 125, 109)	-0.25 (± 1.13)	-0.27 (± 1.09)	-0.44 (± 1.11)
Cough, Week 23 (n=70, 128, 106)	-0.26 (± 1.19)	-0.30 (± 1.07)	-0.45 (± 1.17)
Cough, Week 24 (n=67, 121, 105)	-0.28 (± 1.14)	-0.33 (± 1.00)	-0.46 (± 1.11)
Cough, Week 25 (n=48, 118, 104)	-0.28 (± 1.18)	-0.31 (± 1.09)	-0.52 (± 1.06)
Cough, Week 26 (n=48, 111, 99)	-0.41 (± 1.08)	-0.32 (± 1.09)	-0.54 (± 1.24)
Cough, Week 27 (n=42, 110, 95)	-0.27 (± 1.11)	-0.39 (± 1.10)	-0.31 (± 1.20)
Cough, Week 28 (n=41, 103, 88)	-0.34 (± 1.10)	-0.36 (± 1.07)	-0.52 (± 1.21)
Cough, Week 29 (n=38, 100, 89)	-0.38 (± 1.15)	-0.33 (± 1.06)	-0.48 (± 1.13)
Cough, Week 30 (n=46, 104, 86)	-0.29 (± 1.15)	-0.31 (± 1.02)	-0.54 (± 1.14)
Cough, Week 31 (n=35, 97, 77)	-0.46 (± 1.14)	-0.34 (± 1.11)	-0.49 (± 1.10)
Cough, Week 32 (n=29, 91, 70)	-0.17 (± 0.98)	-0.41 (± 1.02)	-0.53 (± 1.04)
Cough, Week 33 (n=29, 93, 68)	-0.31 (± 1.11)	-0.35 (± 0.97)	-0.53 (± 1.13)
Cough, Week 34 (n=33, 92, 73)	-0.03 (± 0.93)	-0.34 (± 0.84)	-0.41 (± 1.14)
Cough, Week 35 (n=33, 90, 72)	-0.14 (± 1.01)	-0.38 (± 0.91)	-0.47 (± 1.05)
Cough, Week 36 (n=31, 83, 64)	-0.05 (± 0.93)	-0.39 (± 0.96)	-0.43 (± 0.99)
Cough, Week 37 (n=24, 84, 65)	-0.08 (± 1.11)	-0.22 (± 0.94)	-0.54 (± 1.12)
Cough, Week 38 (n=24, 86, 65)	0.02 (± 1.09)	-0.36 (± 0.97)	-0.45 (± 1.16)
Cough, Week 39 (n=25, 75, 68)	0.00 (± 1.05)	-0.46 (± 1.05)	-0.50 (± 1.06)
Cough, Week 40 (n=24, 74, 62)	0.10 (± 1.12)	-0.39 (± 1.04)	-0.47 (± 1.02)
Cough, Week 41 (n=22, 69, 60)	0.07 (± 1.21)	-0.43 (± 1.10)	-0.58 (± 1.06)
Cough, Week 42 (n=24, 77, 60)	-0.04 (± 1.16)	-0.41 (± 1.05)	-0.68 (± 1.05)
Cough, Week 43 (n=23, 72, 58)	-0.02 (± 0.87)	-0.38 (± 1.04)	-0.45 (± 0.99)
Cough, Week 44 (n=20, 63, 60)	-0.05 (± 1.24)	-0.48 (± 1.21)	-0.56 (± 1.09)
Cough, Week 45 (n=20, 64, 51)	0.10 (± 1.24)	-0.32 (± 1.11)	-0.69 (± 1.00)

Cough, Week 46 (n=20, 61, 53)	0.03 (± 0.95)	-0.38 (± 1.11)	-0.67 (± 1.10)
Cough, Week 47 (n=20, 64, 48)	0.10 (± 1.15)	-0.38 (± 1.13)	-0.54 (± 0.97)
Cough, Week 48 (n=19, 62, 52)	0.00 (± 1.22)	-0.41 (± 1.09)	-0.55 (± 1.09)
Cough, Week 49 (n=13, 57, 45)	-0.12 (± 1.04)	-0.44 (± 1.10)	-0.63 (± 1.06)
Cough, Week 50 (n=15, 60, 45)	0.23 (± 0.98)	-0.29 (± 1.16)	-0.72 (± 1.07)
Cough, Week 51 (n=11, 58, 37)	0.05 (± 0.88)	-0.22 (± 1.20)	-0.69 (± 1.11)
Cough, Week 52 (n=13, 58, 43)	0.12 (± 0.79)	-0.33 (± 1.19)	-0.64 (± 1.03)
Cough, Week 53 (n=14, 53, 35)	0.21 (± 0.78)	-0.28 (± 1.14)	-0.53 (± 1.19)
Cough, Week 54 (n=13, 56, 36)	0.08 (± 0.89)	-0.45 (± 1.06)	-0.63 (± 1.23)
Cough, Week 55 (n=12, 47, 36)	0.29 (± 1.05)	-0.38 (± 1.12)	-0.68 (± 1.17)
Cough, Week 56 (n=11, 50, 36)	0.14 (± 1.05)	-0.46 (± 1.13)	-0.51 (± 1.07)
Cough, Week 57 (n=10, 52, 33)	0.10 (± 0.81)	-0.36 (± 1.25)	-0.74 (± 1.10)
Cough, Week 58 (n=8, 45, 29)	0.06 (± 0.94)	-0.51 (± 1.14)	-0.67 (± 1.06)
Cough, Week 59 (n=11, 47, 27)	0.18 (± 0.81)	-0.45 (± 1.19)	-0.81 (± 1.12)
Cough, Week 60 (n=11, 41, 31)	0.14 (± 0.71)	-0.41 (± 1.26)	-0.69 (± 1.04)
Cough, Week 61 (n=9, 40, 28)	0.00 (± 0.97)	-0.38 (± 1.27)	-0.84 (± 1.08)
Cough, Week 62 (n=10, 39, 25)	-0.05 (± 0.86)	-0.29 (± 1.29)	-0.78 (± 1.04)
Cough, Week 63 (n=8, 42, 22)	0.19 (± 0.70)	-0.30 (± 1.09)	-0.82 (± 0.99)
Cough, Week 64 (n=8, 42, 18)	0.13 (± 1.16)	-0.27 (± 1.21)	-0.81 (± 0.93)
Cough, Week 65 (n=6, 39, 20)	0.08 (± 0.97)	-0.28 (± 1.26)	-0.70 (± 1.15)
Cough, Week 66 (n=6, 37, 19)	0.08 (± 0.86)	-0.30 (± 1.22)	-0.82 (± 1.15)
Cough, Week 67 (n=5, 33, 20)	-0.30 (± 0.67)	-0.44 (± 1.29)	-0.78 (± 1.09)
Cough, Week 68 (n=6, 33, 19)	0.00 (± 0.95)	-0.21 (± 1.36)	-0.66 (± 1.17)
Cough, Week 69 (n=5, 31, 18)	0.20 (± 0.91)	-0.26 (± 1.29)	-0.78 (± 1.14)
Cough, Week 70 (n=5, 32, 19)	0.20 (± 0.91)	-0.28 (± 1.13)	-0.92 (± 1.18)
Cough, Week 71 (n=6, 27, 15)	-0.17 (± 1.21)	-0.15 (± 1.01)	-0.90 (± 1.21)
Cough, Week 72 (n=9, 27, 18)	0.00 (± 1.38)	-0.19 (± 1.10)	-0.72 (± 1.05)
Cough, Week 73 (n=60, 27, 13)	0.00 (± 1.38)	-0.22 (± 1.15)	-1.00 (± 1.38)
Cough, Week 74 (n=7, 29, 12)	0.07 (± 0.89)	-0.22 (± 0.97)	-1.04 (± 1.21)
Cough, Week 75 (n=6, 24, 12)	0.08 (± 1.24)	-0.17 (± 1.12)	-1.04 (± 1.29)
Cough, Week 76 (n=6, 23, 14)	0.00 (± 1.38)	0.07 (± 1.16)	-1.18 (± 1.12)
Cough, Week 77 (n=6, 22, 10)	0.25 (± 1.29)	-0.18 (± 1.29)	-0.60 (± 1.05)
Cough, Week 78 (n=7, 22, 11)	0.00 (± 1.26)	-0.30 (± 1.08)	-0.86 (± 1.12)
Cough, Week 79 (n=6, 24, 9)	0.00 (± 1.38)	-0.04 (± 1.04)	-0.61 (± 1.41)
Cough, Week 80 (n=7, 20, 11)	0.21 (± 1.07)	-0.45 (± 1.17)	-0.95 (± 1.13)
Cough, Week 81 (n=6, 18, 9)	0.08 (± 1.02)	-0.31 (± 1.14)	-0.72 (± 1.25)
Cough, Week 82 (n=7, 21, 9)	0.43 (± 1.17)	-0.33 (± 1.06)	-0.44 (± 1.13)
Cough, Week 83 (n=5, 19, 10)	0.30 (± 1.44)	-0.39 (± 1.06)	-1.00 (± 1.20)
Cough, Week 84 (n=5, 15, 10)	0.20 (± 1.30)	-0.10 (± 1.28)	-0.90 (± 1.26)
Cough, Week 85 (n=4, 17, 10)	1.00 (± 0.58)	-0.24 (± 1.13)	-0.60 (± 1.60)
Cough, Week 86 (n=3, 15, 6)	1.17 (± 0.58)	-0.27 (± 1.28)	-0.42 (± 1.32)
Cough, Week 87 (n=3, 12, 8)	0.83 (± 0.58)	0.00 (± 1.30)	-0.94 (± 1.35)
Cough, Week 88 (n=3, 15, 7)	0.67 (± 0.76)	-0.37 (± 1.19)	-1.29 (± 1.41)
Cough, Week 89 (n=3, 14, 7)	0.83 (± 0.58)	-0.29 (± 1.17)	-1.14 (± 1.31)
Cough, Week 90 (n=3, 13, 7)	1.00 (± 0.50)	-0.35 (± 1.14)	-0.79 (± 1.29)
Cough, Week 91 (n=3, 13, 7)	0.67 (± 0.76)	-0.58 (± 1.19)	-0.93 (± 1.37)
Cough, Week 92 (n=4, 13, 8)	1.00 (± 0.58)	-0.19 (± 1.18)	-0.94 (± 1.37)
Cough, Week 93 (n=2, 13, 10)	1.00 (± 0.71)	-0.42 (± 1.26)	-0.90 (± 1.13)
Cough, Week 94 (n=3, 11, 8)	0.83 (± 0.58)	-0.41 (± 1.26)	-0.88 (± 1.25)
Cough, Week 95 (n=3, 11, 8)	0.83 (± 0.58)	0.00 (± 1.28)	-0.81 (± 1.31)
Cough, Week 96 (n=3, 11, 8)	0.83 (± 0.58)	-0.18 (± 1.45)	-1.00 (± 1.31)
Cough, Week 97 (n=3, 11, 9)	1.00 (± 0.50)	-0.14 (± 1.12)	-0.78 (± 1.23)

Cough, Week 98 (n=3, 10, 7)	0.50 (± 0.50)	-0.35 (± 1.18)	-1.00 (± 1.29)
Cough, Week 99 (n=3, 10, 7)	0.83 (± 0.58)	0.00 (± 1.41)	-0.64 (± 1.14)
Cough, Week 100 (n=2, 10, 8)	1.00 (± 0.71)	-0.35 (± 1.16)	-0.81 (± 1.25)
Cough, Week 101 (n=3, 10, 7)	0.83 (± 0.58)	-0.20 (± 1.32)	-0.79 (± 1.32)
Cough, Week 102 (n=3, 6, 6)	0.67 (± 0.76)	0.00 (± 1.30)	-0.75 (± 1.44)
Cough, Week 103 (n=2, 9, 6)	0.50 (± 0.00)	-0.56 (± 1.07)	-0.67 (± 1.44)
Cough, Week 104 (n=2, 8, 4)	0.50 (± 0.00)	-0.38 (± 1.19)	0.00 (± 1.08)
Cough, Week 105 (n=2, 6, 6)	0.50 (± 0.00)	0.08 (± 0.80)	-0.25 (± 1.33)
Cough, Week 106 (n=2, 9, 5)	0.50 (± 0.00)	-0.28 (± 1.23)	-0.80 (± 1.04)
Cough, Week 107 (n=2, 7, 4)	0.25 (± 0.35)	-0.57 (± 1.48)	-1.25 (± 1.19)
Cough, Week 108 (n=2, 5, 4)	0.25 (± 0.35)	-0.70 (± 1.64)	-1.38 (± 1.11)
Cough, Week 109 (n=2, 5, 2)	0.50 (± 0.00)	-0.30 (± 1.82)	-0.75 (± 1.06)
Cough, Week 110 (n=2, 3, 4)	0.50 (± 0.00)	0.50 (± 1.80)	-1.25 (± 1.04)
Cough, Week 111 (n=2, 4, 4)	0.75 (± 0.35)	-0.13 (± 1.93)	-1.25 (± 1.04)
Cough, Week 112 (n=2, 3, 2)	0.50 (± 0.00)	0.17 (± 1.44)	-1.75 (± 0.35)
Cough, Week 113 (n=1, 4, 3)	0.50 (± 999999)	0.13 (± 1.75)	-1.17 (± 1.04)
Cough, Week 114 (n=2, 3, 2)	0.25 (± 0.35)	0.50 (± 1.80)	-1.50 (± 0.71)
Cough, Week 115 (n=2, 4, 3)	0.50 (± 0.00)	-0.88 (± 1.31)	-1.00 (± 1.00)
Cough, Week 116 (n=2, 3, 3)	0.75 (± 0.35)	-0.50 (± 1.32)	-1.33 (± 1.15)
Cough, Week 117 (n=2, 2, 2)	0.75 (± 0.35)	-0.25 (± 1.77)	-1.50 (± 0.71)
Cough, Week 118 (n=1, 1, 2)	0.50 (± 0.80)	1.00 (± 0.76)	-1.50 (± 0.71)
Cough, Week 119 (n=0, 1, 2)	0.13 (± 0.75)	1.00 (± 0.86)	-1.00 (± 0.71)
Cough, Week 120 (n=0, 1, 2)	0.06 (± 0.83)	1.00 (± 0.81)	-1.00 (± 0.71)
Cough, Week 121 (n=0, 1, 2)	0.17 (± 0.89)	1.00 (± 0.83)	-1.00 (± 0.71)
Cough, Week 122 (n=0, 1, 2)	0.21 (± 0.89)	1.00 (± 0.88)	-1.25 (± 0.35)
Cough, Week 123 (n=0, 1, 1)	0.17 (± 0.97)	1.00 (± 0.83)	-2.00 (± 0.88)
Cough, Week 124 (n=0, 1, 1)	0.20 (± 0.98)	2.00 (± 0.91)	-1.00 (± 0.96)
Cough, Week 125 (n=0, 0, 1)	0.26 (± 0.95)	0.29 (± 0.91)	-2.00 (± 0.97)
Cough, Week 126 (n=0, 0, 1)	0.23 (± 0.97)	0.26 (± 0.85)	-1.00 (± 0.98)
Cough, Week 127 (n=0, 0, 1)	0.37 (± 0.99)	0.34 (± 0.94)	-1.00 (± 0.95)
Cough, Time of First Pd (n=103, 107, 106)	-0.15 (± 1.05)	-0.16 (± 1.12)	-0.16 (± 1.05)
Cough, Time of Last Tx Dose (n=161, 172, 151)	-0.31 (± 1.10)	-0.24 (± 1.09)	-0.21 (± 1.13)
Cough, Survival FU Month 1 (n=86, 0, 0)	-0.03 (± 1.13)	0.32 (± 0.92)	0.34 (± 0.94)
Cough, Survival FU Month 2 (n=52, 0, 0)	0.03 (± 1.04)	0.29 (± 0.92)	0.34 (± 0.91)
Cough, Survival FU Month 3 (n=40, 0, 0)	-0.18 (± 1.06)	0.32 (± 0.92)	0.30 (± 0.91)
Cough, Survival FU Month 4 (n=32, 0, 0)	-0.09 (± 1.32)	0.32 (± 0.93)	0.36 (± 0.92)
Cough, Survival FU Month 5 (n=26, 0, 0)	-0.04 (± 1.14)	0.25 (± 0.90)	0.29 (± 0.91)
Cough, Survival FU Month 6 (n=23, 0, 0)	-0.17 (± 1.17)	0.28 (± 0.93)	0.34 (± 0.97)
Cough, Survival FU Month 7 (n=3, 0, 0)	1.33 (± 0.29)	0.28 (± 0.98)	0.44 (± 0.96)
Cough, Survival FU Month 8 (n=2, 0, 0)	-0.50 (± 2.12)	0.28 (± 0.93)	0.24 (± 0.99)
Dyspnoea, Week 1 (n=171, 192, 166)	0.18 (± 0.80)	0.11 (± 0.76)	0.17 (± 0.73)
Dyspnoea, Week 2 (n=160, 186, 165)	0.13 (± 0.75)	0.11 (± 0.86)	0.27 (± 0.88)
Dyspnoea, Week 3 (n=165, 175, 165)	0.06 (± 0.83)	0.16 (± 0.81)	0.30 (± 0.89)
Dyspnoea, Week 4 (n=157, 173, 169)	0.17 (± 0.89)	0.16 (± 0.83)	0.26 (± 0.89)
Dyspnoea, Week 5 (n=160, 172, 159)	0.21 (± 0.89)	0.25 (± 0.88)	0.31 (± 0.85)
Dyspnoea, Week 6 (n=151, 170, 161)	0.17 (± 0.97)	0.23 (± 0.83)	0.29 (± 0.88)

Dyspnoea, Week 7 (n=138, 166, 143)	0.20 (± 0.98)	0.25 (± 0.91)	0.27 (± 0.96)
Dyspnoea, Week 8 (n=140, 162, 152)	0.26 (± 0.95)	0.29 (± 0.91)	0.31 (± 0.97)
Dyspnoea, Week 9 (n=135, 162, 143)	0.23 (± 0.97)	0.26 (± 0.85)	0.33 (± 0.98)
Dyspnoea, Week 10 (n=133, 158, 146)	0.37 (± 0.99)	0.34 (± 0.94)	0.34 (± 0.95)
Dyspnoea, Week 11 (n=132, 157, 137)	0.40 (± 0.95)	0.31 (± 0.91)	0.35 (± 0.97)
Dyspnoea, Week 12 (n=128, 151, 136)	0.44 (± 0.98)	0.41 (± 1.01)	0.29 (± 0.90)
Dyspnoea, Week 13 (n=117, 144, 130)	0.40 (± 1.03)	0.32 (± 0.92)	0.34 (± 0.94)
Dyspnoea, Week 14 (n=105, 139, 138)	0.42 (± 0.95)	0.29 (± 0.92)	0.34 (± 0.91)
Dyspnoea, Week 15 (n=97, 143, 132)	0.36 (± 0.98)	0.32 (± 0.92)	0.30 (± 0.91)
Dyspnoea, Week 16 (n=102, 138, 121)	0.45 (± 0.95)	0.32 (± 0.93)	0.36 (± 0.92)
Dyspnoea, Week 17 (n=101, 135, 129)	0.55 (± 0.99)	0.25 (± 0.90)	0.29 (± 0.91)
Dyspnoea, Week 18 (n=93, 141, 129)	0.46 (± 0.93)	0.28 (± 0.93)	0.34 (± 0.97)
Dyspnoea, Week 19 (n=85, 129, 118)	0.48 (± 0.97)	0.28 (± 0.98)	0.44 (± 0.96)
Dyspnoea, Week 20 (n=75, 130, 114)	0.37 (± 0.97)	0.28 (± 0.93)	0.24 (± 0.99)
Dyspnoea, Week 21 (n=69, 129, 113)	0.51 (± 0.94)	0.23 (± 0.98)	0.19 (± 1.00)
Dyspnoea, Week 22 (n=79, 125, 109)	0.50 (± 0.95)	0.25 (± 0.96)	0.24 (± 1.07)
Dyspnoea, Week 23 (n=70, 128, 106)	0.44 (± 0.94)	0.30 (± 0.99)	0.20 (± 0.98)
Dyspnoea, Week 24 (n=67, 121, 105)	0.25 (± 1.01)	0.20 (± 0.91)	0.29 (± 1.02)
Dyspnoea, Week 25 (n=48, 118, 104)	0.27 (± 0.94)	0.18 (± 0.95)	0.25 (± 1.00)
Dyspnoea, Week 26 (n=48, 111, 99)	0.20 (± 0.84)	0.31 (± 0.96)	0.39 (± 1.02)
Dyspnoea, Week 27 (n=42, 110, 95)	0.31 (± 0.80)	0.21 (± 0.95)	0.36 (± 1.14)
Dyspnoea, Week 28 (n=41, 103, 88)	0.24 (± 0.83)	0.17 (± 0.86)	0.30 (± 1.07)
Dyspnoea, Week 29 (n=38, 100, 89)	0.30 (± 0.82)	0.19 (± 0.96)	0.31 (± 1.07)
Dyspnoea, Week 30 (n=46, 104, 86)	0.30 (± 0.82)	0.12 (± 0.94)	0.39 (± 1.08)
Dyspnoea, Week 31 (n=35, 97, 77)	0.34 (± 0.76)	0.18 (± 0.96)	0.36 (± 1.12)
Dyspnoea, Week 32 (n=29, 91, 70)	0.28 (± 0.79)	0.09 (± 0.84)	0.26 (± 1.05)
Dyspnoea, Week 33 (n=29, 93, 68)	0.39 (± 0.74)	0.02 (± 0.85)	0.31 (± 1.05)
Dyspnoea, Week 34 (n=33, 92, 73)	0.32 (± 0.69)	0.05 (± 0.76)	0.30 (± 1.05)
Dyspnoea, Week 35 (n=33, 90, 72)	0.35 (± 0.88)	0.04 (± 0.82)	0.38 (± 1.05)
Dyspnoea, Week 36 (n=31, 83, 64)	0.32 (± 0.68)	0.11 (± 0.82)	0.37 (± 0.98)
Dyspnoea, Week 37 (n=24, 84, 65)	0.24 (± 0.76)	0.16 (± 0.92)	0.32 (± 0.92)
Dyspnoea, Week 38 (n=24, 86, 65)	0.31 (± 0.75)	0.10 (± 0.78)	0.40 (± 1.01)
Dyspnoea, Week 39 (n=25, 75, 68)	0.39 (± 0.76)	0.04 (± 0.87)	0.36 (± 1.01)
Dyspnoea, Week 40 (n=24, 74, 62)	0.38 (± 0.74)	0.24 (± 0.92)	0.37 (± 0.91)
Dyspnoea, Week 41 (n=22, 69, 60)	0.45 (± 0.92)	0.13 (± 0.84)	0.33 (± 0.89)
Dyspnoea, Week 42 (n=24, 77, 60)	0.37 (± 0.82)	0.05 (± 0.81)	0.29 (± 1.02)
Dyspnoea, Week 43 (n=23, 72, 58)	0.48 (± 0.94)	0.16 (± 0.76)	0.41 (± 1.05)
Dyspnoea, Week 44 (n=20, 63, 60)	0.22 (± 0.95)	0.11 (± 0.88)	0.33 (± 1.08)
Dyspnoea, Week 45 (n=20, 64, 51)	0.32 (± 1.04)	0.20 (± 0.84)	0.27 (± 1.07)
Dyspnoea, Week 46 (n=20, 61, 53)	0.36 (± 0.98)	0.08 (± 0.78)	0.26 (± 0.99)
Dyspnoea, Week 47 (n=20, 64, 48)	0.32 (± 0.85)	0.06 (± 0.80)	0.31 (± 1.01)
Dyspnoea, Week 48 (n=19, 62, 52)	0.32 (± 0.88)	0.14 (± 0.85)	0.22 (± 0.93)
Dyspnoea, Week 49 (n=13, 57, 45)	0.46 (± 0.99)	0.06 (± 0.78)	0.14 (± 0.93)
Dyspnoea, Week 50 (n=15, 60, 45)	0.41 (± 0.84)	0.10 (± 0.85)	0.06 (± 0.86)
Dyspnoea, Week 51 (n=11, 58, 37)	0.71 (± 0.92)	0.08 (± 0.78)	0.15 (± 1.06)
Dyspnoea, Week 52 (n=13, 58, 43)	0.60 (± 0.81)	0.11 (± 0.86)	0.34 (± 0.97)
Dyspnoea, Week 53 (n=14, 53, 35)	0.70 (± 0.85)	0.11 (± 0.89)	0.11 (± 1.11)
Dyspnoea, Week 54 (n=13, 56, 36)	0.71 (± 0.94)	0.11 (± 0.80)	0.10 (± 1.02)
Dyspnoea, Week 55 (n=12, 47, 36)	0.82 (± 0.93)	0.15 (± 0.85)	0.16 (± 1.08)
Dyspnoea, Week 56 (n=11, 50, 36)	0.69 (± 0.94)	0.14 (± 0.95)	0.12 (± 1.02)
Dyspnoea, Week 57 (n=10, 52, 33)	0.74 (± 0.80)	0.12 (± 0.90)	0.13 (± 1.03)
Dyspnoea, Week 58 (n=8, 45, 29)	0.80 (± 0.93)	0.02 (± 0.98)	0.12 (± 1.06)

Dyspnoea, Week 59 (n=11, 47, 27)	0.78 (± 1.09)	0.11 (± 1.00)	-0.03 (± 1.04)
Dyspnoea, Week 60 (n=11, 41, 31)	0.67 (± 0.86)	0.06 (± 0.93)	0.02 (± 1.02)
Dyspnoea, Week 61 (n=9, 40, 28)	0.91 (± 0.91)	0.05 (± 0.92)	-0.18 (± 0.93)
Dyspnoea, Week 62 (n=10, 39, 25)	0.58 (± 0.94)	0.01 (± 0.96)	-0.04 (± 1.01)
Dyspnoea, Week 63 (n=8, 42, 22)	0.58 (± 1.14)	0.10 (± 0.95)	-0.06 (± 0.72)
Dyspnoea, Week 64 (n=8, 42, 18)	0.63 (± 0.98)	0.07 (± 1.08)	-0.22 (± 0.74)
Dyspnoea, Week 65 (n=6, 39, 20)	0.80 (± 1.06)	0.05 (± 1.05)	-0.18 (± 0.87)
Dyspnoea, Week 66 (n=6, 37, 19)	0.70 (± 1.02)	0.04 (± 1.07)	-0.18 (± 0.85)
Dyspnoea, Week 67 (n=5, 33, 20)	0.52 (± 0.95)	0.04 (± 1.15)	-0.24 (± 0.97)
Dyspnoea, Week 68 (n=6, 33, 19)	0.63 (± 0.98)	0.01 (± 1.07)	-0.11 (± 0.86)
Dyspnoea, Week 69 (n=5, 31, 18)	0.96 (± 0.59)	0.06 (± 1.19)	-0.20 (± 0.87)
Dyspnoea, Week 70 (n=5, 32, 19)	1.00 (± 0.60)	0.16 (± 1.08)	-0.18 (± 0.94)
Dyspnoea, Week 71 (n=6, 27, 15)	0.70 (± 0.91)	0.22 (± 1.08)	-0.01 (± 0.82)
Dyspnoea, Week 72 (n=6, 27, 18)	0.57 (± 0.98)	0.25 (± 1.16)	-0.06 (± 0.79)
Dyspnoea, Week 73 (n=6, 27, 13)	0.67 (± 1.07)	0.10 (± 1.18)	-0.11 (± 0.79)
Dyspnoea, Week 74 (n=7, 29, 12)	0.74 (± 0.96)	0.10 (± 1.15)	-0.17 (± 0.86)
Dyspnoea, Week 75 (n=6, 24, 12)	0.70 (± 0.99)	0.05 (± 1.13)	-0.22 (± 0.81)
Dyspnoea, Week 76 (n=6, 23, 14)	0.67 (± 0.90)	0.25 (± 1.33)	-0.13 (± 0.90)
Dyspnoea, Week 77 (n=6, 22, 10)	0.73 (± 0.95)	0.04 (± 1.36)	0.12 (± 0.76)
Dyspnoea, Week 78 (n=7, 22, 11)	0.57 (± 0.94)	0.09 (± 1.24)	-0.20 (± 0.95)
Dyspnoea, Week 79 (n=6, 24, 9)	0.57 (± 0.77)	0.16 (± 1.29)	-0.13 (± 0.93)
Dyspnoea, Week 80 (n=7, 20, 11)	0.60 (± 0.78)	-0.13 (± 1.17)	0.00 (± 0.81)
Dyspnoea, Week 81 (n=6, 18, 9)	0.50 (± 0.92)	-0.02 (± 1.17)	-0.04 (± 0.86)
Dyspnoea, Week 82 (n=7, 21, 9)	0.57 (± 0.91)	-0.05 (± 1.16)	0.00 (± 0.90)
Dyspnoea, Week 83 (n=5, 19, 10)	0.28 (± 0.69)	-0.08 (± 1.26)	-0.40 (± 0.98)
Dyspnoea, Week 84 (n=5, 15, 10)	0.16 (± 0.59)	-0.17 (± 1.23)	-0.22 (± 0.99)
Dyspnoea, Week 85 (n=4, 17, 10)	0.70 (± 0.50)	-0.16 (± 1.11)	-0.16 (± 1.03)
Dyspnoea, Week 86 (n=3, 15, 6)	1.33 (± 1.45)	-0.23 (± 1.12)	-0.17 (± 1.26)
Dyspnoea, Week 87 (n=3, 12, 8)	0.40 (± 0.40)	0.08 (± 1.45)	-0.25 (± 1.06)
Dyspnoea, Week 88 (n=3, 15, 7)	0.40 (± 0.69)	-0.21 (± 1.06)	-0.51 (± 1.06)
Dyspnoea, Week 89 (n=3, 14, 7)	0.53 (± 0.42)	-0.13 (± 1.02)	-0.06 (± 1.12)
Dyspnoea, Week 90 (n=3, 13, 7)	0.27 (± 0.31)	-0.32 (± 0.99)	-0.17 (± 1.07)
Dyspnoea, Week 91 (n=3, 13, 7)	0.33 (± 0.31)	-0.52 (± 0.81)	-0.17 (± 1.13)
Dyspnoea, Week 92 (n=4, 13, 8)	0.75 (± 0.66)	-0.28 (± 1.02)	-0.10 (± 1.06)
Dyspnoea, Week 93(n=2, 13, 10)	0.40 (± 0.28)	-0.23 (± 0.93)	-0.14 (± 0.90)
Dyspnoea, Week 94 (n=3, 11, 8)	0.67 (± 0.70)	-0.38 (± 0.85)	-0.25 (± 0.98)
Dyspnoea, Week 95 (n=3, 11, 8)	0.53 (± 0.23)	-0.07 (± 1.21)	-0.20 (± 1.04)
Dyspnoea, Week 96 (n=3, 11, 8)	0.33 (± 0.42)	-0.02 (± 1.21)	-0.18 (± 1.09)
Dyspnoea, Week 97 (n=3, 11, 9)	0.67 (± 0.42)	-0.22 (± 1.18)	0.04 (± 1.13)
Dyspnoea, Week 98 (n=3, 10, 7)	0.73 (± 0.50)	-0.18 (± 1.19)	-0.29 (± 1.08)
Dyspnoea, Week 99 (n=3, 10, 7)	0.47 (± 0.46)	-0.26 (± 1.25)	-0.29 (± 1.09)
Dyspnoea, Week 100 (n=2, 10, 8)	0.50 (± 0.42)	-0.24 (± 1.24)	-0.20 (± 1.08)
Dyspnoea, Week 101 (n=3, 10, 7)	0.40 (± 0.35)	-0.26 (± 1.23)	-0.03 (± 1.09)
Dyspnoea, Week 102 (n=3, 6, 9)	0.40 (± 0.35)	-0.67 (± 0.89)	0.00 (± 1.08)
Dyspnoea, Week 103 (n=2, 9, 6)	0.70 (± 0.42)	-0.60 (± 0.73)	-0.03 (± 1.24)
Dyspnoea, Week 104 (n=2, 8, 4)	0.50 (± 0.71)	-0.63 (± 0.82)	-0.35 (± 1.42)
Dyspnoea, Week 105 (n=2, 6, 6)	0.40 (± 0.57)	-0.20 (± 0.33)	0.23 (± 0.92)
Dyspnoea, Week 106 (n=2, 9, 5)	0.30 (± 0.42)	-0.24 (± 0.31)	-0.04 (± 0.57)
Dyspnoea, Week 107(n=2, 7, 4)	0.60 (± 0.28)	-0.17 (± 0.35)	-0.30 (± 0.74)
Dyspnoea, Week 108 (n=2, 5, 4)	0.60 (± 0.28)	-0.36 (± 0.43)	-0.40 (± 0.88)
Dyspnoea, Week 109(n=2, 5, 2)	0.80 (± 0.00)	-0.40 (± 0.47)	0.10 (± 0.99)
Dyspnoea, Week 110(n=2, 3, 4)	0.60 (± 0.28)	-0.27 (± 0.50)	-0.40 (± 0.94)

Dyspnoea, Week 111 (n=2, 4, 4)	0.30 (± 0.42)	-0.15 (± 0.34)	-0.45 (± 0.91)
Dyspnoea, Week 112 (n=2, 3, 2)	0.50 (± 0.42)	-0.20 (± 0.40)	-1.30 (± 0.14)
Dyspnoea, Week 113(n=1, 4, 3)	1.00 (± 999999)	-0.35 (± 0.44)	-0.47 (± 1.14)
Dyspnoea, Week 114(n=2, 3, 2)	0.50 (± 0.71)	-0.27 (± 0.50)	-1.30 (± 0.14)
Dyspnoea, Week 115(n=2, 4, 3)	0.50 (± 0.71)	-0.40 (± 0.28)	-0.67 (± 1.10)
Dyspnoea, Week 116(n=2, 3, 3)	0.40 (± 0.57)	-0.20 (± 0.53)	-0.73 (± 1.17)
Dyspnoea, Week 117(n=2, 2, 2)	0.40 (± 0.28)	-0.60 (± 0.28)	-1.20 (± 0.28)
Dyspnoea, Week 118 (n=1, 1, 2)	1.00 (± 999999)	-0.80 (± 999999)	-1.20 (± 0.57)
Dyspnoea, Week 119(n=0, 1, 2)	999999 (± 999999)	-0.80 (± 999999)	-1.40 (± 0.28)
Dyspnoea, Week 120 (n=0, 1, 2)	999999 (± 999999)	-0.80 (± 999999)	-1.10 (± 0.42)
Dyspnoea, Week 121 (n=0, 1, 2)	999999 (± 999999)	-0.80 (± 999999)	-1.30 (± 0.14)
Dyspnoea, Week 122(n=0, 1, 2)	999999 (± 999999)	-0.80 (± 999999)	-1.30 (± 0.14)
Dyspnoea, Week 123(n=0, 1, 1)	999999 (± 999999)	-0.80 (± 999999)	-1.00 (± 999999)
Dyspnoea, Week 124 (n=0, 1, 1)	999999 (± 999999)	-0.80 (± 999999)	-1.20 (± 999999)
Dyspnoea, Week 125 (n=0, 0, 1)	999999 (± 999999)	999999 (± 999999)	-1.00 (± 999999)
Dyspnoea, Week 126 (n=0, 0, 1)	999999 (± 999999)	999999 (± 999999)	-1.20 (± 999999)
Dyspnoea, Week 127(n=0, 0, 1)	999999 (± 999999)	999999 (± 999999)	-1.20 (± 999999)
Dyspnoea, Time of First Pd (n=103, 107, 106)	0.38 (± 1.06)	0.42 (± 0.95)	0.27 (± 1.13)
Dyspnoea, Time of Last Tx Dose (n=161, 172, 151)	0.43 (± 0.91)	0.28 (± 1.01)	0.28 (± 1.00)
Dyspnoea, Survival FU Month 1 (n=86, 0, 0)	0.56 (± 1.09)	999999 (± 999999)	999999 (± 999999)
Dyspnoea, Survival FU Month 2 (n=52, 0, 0)	0.71 (± 0.89)	999999 (± 999999)	999999 (± 999999)
Dyspnoea, Survival FU Month 3 (n=40, 0, 0)	0.67 (± 1.06)	999999 (± 999999)	999999 (± 999999)
Dyspnoea, Survival FU Month 4 (n=32, 0, 0)	0.57 (± 0.91)	999999 (± 999999)	999999 (± 999999)
Dyspnoea, Survival FU Month 5 (n=29, 0, 0)	0.66 (± 1.02)	999999 (± 999999)	999999 (± 999999)
Dyspnoea, Survival FU Month 6 (n=23, 0, 0)	0.63 (± 1.09)	999999 (± 999999)	999999 (± 999999)
Dyspnoea, Survival FU Month 7 (n=3, 0, 0)	1.07 (± 1.36)	999999 (± 999999)	999999 (± 999999)
Dyspnoea, Survival FU Month 8 (n=2, 0, 0)	0.10 (± 0.14)	999999 (± 999999)	999999 (± 999999)

Statistical analyses

No statistical analyses for this end point

Secondary: PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B)

End point title	PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B) ^[1]
-----------------	--

End point description:

PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT Population Arm A and Arm B.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 30 months after first participant enrolled

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis for this endpoint.

End point values	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	343	338		
Units: Months				
median (confidence interval 95%)	6.5 (5.7 to 7.1)	5.6 (5.5 to 6.9)		

Statistical analyses

Statistical analysis title	PFS in ITT
Comparison groups	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	681
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.4007
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.784
upper limit	1.102

Secondary: OS in the ITT Population (Arm A and Arm B)

End point title	OS in the ITT Population (Arm A and Arm B) ^[2]
-----------------	---

End point description:

OS is defined as the time between the date of randomization and date of death from any cause in the ITT Population, Arm A and Arm B.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 39 months after first participant enrolled

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis for this endpoint.

End point values	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	343	338		
Units: Months				
median (confidence interval 95%)	14.2 (12.3 to 16.8)	12.6 (11.6 to 14.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Adverse Events

End point title	Percentage of Participants With Adverse Events
End point description: Percentage of participants with at least one adverse event.	
End point type	Secondary
End point timeframe: Up to approximately 68 months after first participant enrolled	

End point values	Arm C: Nab- Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	334	334	332	
Units: Percentage of participants				
number (not applicable)	28.7	50.3	45.5	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Anti-therapeutic Antibody (ATA) Response to Atezolizumab

End point title	Percentage of Participants with Anti-therapeutic Antibody (ATA) Response to Atezolizumab ^[3]
End point description: Percentage of participants with Anti-therapeutic Antibody (ATA) response to atezolizumab.	
End point type	Secondary

End point timeframe:

Up to approximately 30 months after first participant enrolled

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis for this endpoint.

End point values	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	343	338		
Units: Percentage of participants				
number (not applicable)				
Baseline evaluable participants	1.9	3.1		
Post-baseline evaluable participants	21.4	48.1		

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Serum Atezolizumab Concentration (Cmax)

End point title	Maximum Observed Serum Atezolizumab Concentration
-----------------	---

End point description:

Maximum observed serum atezolizumab concentration (Cmax). The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis for this endpoint.

End point values	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	328	327		
Units: µg/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1 Post dose	378 (± 124)	372 (± 116)		
Cycle 3 Day 1 Post dose	444 (± 119)	470 (± 147)		

Statistical analyses

Secondary: Minimum Observed Serum Atezolizumab Concentration (Cmin)

End point title	Minimum Observed Serum Atezolizumab Concentration
-----------------	---

End point description:

Minimum observed serum atezolizumab concentration (Cmin). The predose samples will be collected on the same day of treatment administration. (Note: 888888=Non-reportable. 777777=Not evaluable.)

End point type	Secondary
----------------	-----------

End point timeframe:

Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 30 months), at treatment discontinuation (up to 30 months), and at 120 days after the last dose of atezolizumab (up to approximately 30 months, each cycle is 21 days)

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis for this endpoint.

End point values	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	328	327		
Units: µg/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	888888 (± 888888)	888888 (± 888888)		
Cycle 2 Day 1	69.5 (± 34.7)	63.9 (± 29.9)		
Cycle 3 Day 1	107 (± 52.0)	103 (± 40.1)		
Cycle 4 Day 1	126 (± 68.4)	128 (± 62.3)		
Cycle 8 Day 1	190 (± 84.6)	188 (± 80.4)		
Cycle 16 Day 1	212 (± 78.1)	201 (± 79.2)		
Cycle 24 Day 1	224 (± 134)	187 (± 90.4)		
Cycle 32 Day 1	210 (± 102)	242 (± 88.4)		
Cycle 40 Day 1	174 (± 777777)	308 (± 141)		
Treatment Discontinuation Visit	137 (± 103)	126 (± 93.7)		
Day 120 Post Last Dose	9.47 (± 13.1)	7.81 (± 9.76)		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations for Paclitaxel

End point title	Plasma Concentrations for Paclitaxel ^[6]
-----------------	---

End point description:

Plasma concentrations for paclitaxel. (Note: 888888=Non-reportable.)

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each

cycle is 21 days)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis for this endpoint.

End point values	Arm A: Atezolizumab + Paclitaxel + Carboplatin			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1 Prior to Infusion	888888 (± 888888)			
Cycle 1 Day 1 Before end of Infusion	5860 (± 2410)			
Cycle 1 Day 1 After Infusion	2960 (± 2770)			
Cycle 3 Day 1 Prior to Infusion	888888 (± 888888)			
Cycle 3 Day 1 Before end of Infusion	21900 (± 42600)			
Cycle 3 Day 1 After Infusion	11000 (± 30700)			

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations for Nab-Paclitaxel

End point title	Plasma Concentrations for Nab-Paclitaxel ^[7]
End point description:	Plasma concentrations for nab-paclitaxel. (Note: 888888=Non-reportable.)
End point type	Secondary
End point timeframe:	Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis for this endpoint.

End point values	Arm C: Nab- Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	32		
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1 Prior to Infusion	888888 (± 888888)	888888 (± 888888)		

Cycle 1 Day 1 Before End of Infusion	8160 (\pm 20900)	3330 (\pm 3680)		
Cycle 1 Day 1 After Infusion	921 (\pm 2080)	735 (\pm 1300)		
Cycle 3 Day 1 Prior to Infusion	888888 (\pm 888888)	888888 (\pm 888888)		
Cycle 3 Day 1 Before End of Infusion	7180 (\pm 14400)	7160 (\pm 12300)		
Cycle 3 Day 1 After Infusion	1140 (\pm 2070)	296 (\pm 274)		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations for Carboplatin

End point title	Plasma Concentrations for Carboplatin
End point description:	Plasma concentrations for carboplatin. (Note: 888888=Non-reportable.)
End point type	Secondary
End point timeframe:	Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	39	33	34	
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1 Prior to Infusion	888888 (\pm 888888)	888888 (\pm 888888)	888888 (\pm 888888)	
Cycle 1 Day 1 Before End of Infusion	24900 (\pm 38200)	15900 (\pm 9270)	21100 (\pm 12400)	
Cycle 1 Day 1 After Infusion	10800 (\pm 6230)	9890 (\pm 4780)	11900 (\pm 6410)	
Cycle 3 Day 1 Prior to Infusion	161 (\pm 70.0)	147 (\pm 60.9)	238 (\pm 276)	
Cycle 3 Day 1 Before End of Infusion	26800 (\pm 31900)	23500 (\pm 21600)	33800 (\pm 38600)	
Cycle 3 Day 1 After Infusion	14700 (\pm 14600)	11200 (\pm 5160)	20000 (\pm 30900)	

Statistical analyses

No statistical analyses for this end point

Secondary: OS in the in the Teff Population

End point title	OS in the in the Teff Population
End point description: OS is defined as the time between the date of randomization and date of death from any cause in the in the Teff Population.	
End point type	Secondary
End point timeframe: Up to approximately 39 months after first participant enrolled	

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	322	313	308	
Units: Month				
median (confidence interval 95%)				
Teff >=-1.91 (n=147, 124, 123)	16.4 (12.2 to 19.7)	17.4 (12.3 to 23.8)	15.2 (13.4 to 22.8)	
Teff<-1.91 (n=175, 189, 185)	12.4 (11.2 to 14.3)	13.0 (11.4 to 14.8)	10.5 (9.1 to 12.6)	

Statistical analyses

Statistical analysis title	OS Teff >=-1.91 in ITT Population
Statistical analysis description: Teff >=-1.91 in ITT	
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.4451
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.876
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.623
upper limit	1.231

Statistical analysis title	OS Teff >=-1.91 in ITT Population
Statistical analysis description: Teff >=-1.91 in ITT	
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin

Number of subjects included in analysis	630
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.7343
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.941
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.664
upper limit	1.335

Statistical analysis title	OS Teff <-1.91 Negative in ITT Population
Statistical analysis description: Teff <-1.91 Negative in ITT	
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.661
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.942
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.72
upper limit	1.232

Statistical analysis title	OS Teff <-1.91 Negative in ITT Population
Statistical analysis description: Teff <-1.91 Negative in ITT	
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	630
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0893
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.253

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.965
upper limit	1.627

Secondary: PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population

End point title	PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population
End point description:	
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Teff Population.	
End point type	Secondary
End point timeframe:	
Up to approximately 30 months after first participant enrolled	

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	322	313	308	
Units: Months				
median (confidence interval 95%)				
Teff >=-1.91 (n=147, 124, 123)	5.6 (5.1 to 5.7)	7.0 (5.5 to 8.5)	7.0 (5.6 to 9.7)	
Teff <-1.91 (n=175, 189, 185)	5.7 (5.5 to 6.6)	6.2 (5.6 to 7.0)	5.5 (4.5 to 5.6)	

Statistical analyses

Statistical analysis title	PFS in Teff>=-1.91 Population
Statistical analysis description:	
Teff>=-1.91	
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0006
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.61

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.46
upper limit	0.81

Statistical analysis title	PFS in Teff>=-1.91 Population
Statistical analysis description: Teff>=-1.91	
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	630
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.63
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	1.33

Statistical analysis title	PFS in Teff<-1.91 Population
Statistical analysis description: Teff<-1.91	
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.258
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.1

Statistical analysis title	PFS in Teff<-1.91 Population
-----------------------------------	------------------------------

Statistical analysis description:

Teff<-1.91

Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	630
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.63
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	1.33

Secondary: Event Free Rate at 1 and 2 Years in the ITT Population

End point title	Event Free Rate at 1 and 2 Years in the ITT Population
-----------------	--

End point description:

Event free rate at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

1 and 2 years

End point values	Arm C: Nab-Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	184	187	170	
Units: Percentage of participants				
number (not applicable)				
1 Year (n=184, 187, 170)	56.28	56.34	52.30	
2 Year (n=49, 68, 50)	26.58	32.51	27.79	

Statistical analyses

Statistical analysis title	Event Free Rate in ITT Population
-----------------------------------	-----------------------------------

Statistical analysis description:

Event Free Rate (%) at Year 1

Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
-------------------	--

Number of subjects included in analysis	371
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.9871
Method	Z-test
Parameter estimate	Difference in Event Free Rate
Point estimate	0.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.48
upper limit	7.61

Statistical analysis title	Event Free Rate in ITT Population
Statistical analysis description: Event Free Rate (%) at Year 2	
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Number of subjects included in analysis	371
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1133
Method	Z-test
Parameter estimate	Difference in Event Free Rate
Point estimate	5.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.41
upper limit	13.26

Statistical analysis title	Event Free Rate in ITT Population
Statistical analysis description: Event Free Rate (%) at Year 1	
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	354
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3072
Method	Z-test
Parameter estimate	Difference in Event Free Rate
Point estimate	-3.97

Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.6
upper limit	3.65

Statistical analysis title	Event Free Rate in ITT Population
Statistical analysis description:	
Event Free Rate (%) at Year 2	
Comparison groups	Arm C: Nab-Paclitaxel + Carboplatin v Arm A: Atezolizumab + Paclitaxel + Carboplatin
Number of subjects included in analysis	354
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.743
Method	Z-test
Parameter estimate	Difference in Event Free Rate
Point estimate	1.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.01
upper limit	8.42

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the first study drug administration to the data cutoff date: 17 February 2021 (up to approximately 68 months).

Adverse event reporting additional description:

Safety-evaluable population included all participants who received at least one dose of any study medication.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22
--------------------	----

Reporting groups

Reporting group title	Arm C: Nab-Paclitaxel + Carboplatin
-----------------------	-------------------------------------

Reporting group description:

The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care.

Reporting group title	Arm A: Atezolizumab + Paclitaxel + Carboplatin
-----------------------	--

Reporting group description:

The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.

Reporting group title	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
-----------------------	--

Reporting group description:

The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.

Serious adverse events	Arm C: Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Total subjects affected by serious adverse events			
subjects affected / exposed	96 / 334 (28.74%)	151 / 332 (45.48%)	168 / 334 (50.30%)
number of deaths (all causes)	265	248	244
number of deaths resulting from adverse events	3	9	5
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ADENOCARCINOMA OF COLON			

subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PROSTATE CANCER			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TUMOUR EMBOLISM			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
BENIGN SALIVARY GLAND NEOPLASM			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFECTED NEOPLASM			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
BLADDER CANCER			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLON CANCER			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GALLBLADDER ADENOCARCINOMA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MYELODYSPLASTIC SYNDROME			

subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Vascular disorders			
EMBOLISM			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
DEEP VEIN THROMBOSIS			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERIPHERAL ISCHAEMIA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ARTERITIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOSIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPOTENSION			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HAEMODYNAMIC INSTABILITY			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE			

subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ORTHOSTATIC HYPOTENSION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ARTERIAL STENOSIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUPERIOR VENA CAVA SYNDROME			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Surgical and medical procedures			
TRANSURETHRAL PROSTATECTOMY			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THERAPEUTIC EMBOLISATION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
OEDEMA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

PYREXIA			
subjects affected / exposed	5 / 334 (1.50%)	6 / 332 (1.81%)	6 / 334 (1.80%)
occurrences causally related to treatment / all	3 / 6	3 / 8	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PAIN			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FATIGUE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	3 / 334 (0.90%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASTHENIA			
subjects affected / exposed	1 / 334 (0.30%)	2 / 332 (0.60%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHEST PAIN			
subjects affected / exposed	2 / 334 (0.60%)	3 / 332 (0.90%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERFORMANCE STATUS DECREASED			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUCOSAL INFLAMMATION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEATH			
subjects affected / exposed	0 / 334 (0.00%)	2 / 332 (0.60%)	8 / 334 (2.40%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 8
deaths causally related to treatment / all	0 / 0	1 / 2	0 / 8
MALAISE			

subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GAIT DISTURBANCE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DRUG HYPERSENSITIVITY			
subjects affected / exposed	0 / 334 (0.00%)	2 / 332 (0.60%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAPHYLACTIC REACTION			
subjects affected / exposed	0 / 334 (0.00%)	2 / 332 (0.60%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
PROSTATITIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
DIAPHRAGMATIC PARALYSIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSPNOEA			

subjects affected / exposed	3 / 334 (0.90%)	8 / 332 (2.41%)	7 / 334 (2.10%)
occurrences causally related to treatment / all	0 / 4	0 / 8	1 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
DYSпноEA AT REST			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUNG DISORDER			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPOXIA			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INTERSTITIAL LUNG DISEASE			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
IMMUNE-MEDIATED PNEUMONITIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EMPHYSEMA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EPISTAXIS			

subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	1 / 1	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUNG CONSOLIDATION			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA ASPIRATION			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONITIS			
subjects affected / exposed	2 / 334 (0.60%)	10 / 332 (3.01%)	10 / 334 (2.99%)
occurrences causally related to treatment / all	2 / 2	10 / 10	10 / 10
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
PARANASAL CYST			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COUGH			
subjects affected / exposed	0 / 334 (0.00%)	2 / 332 (0.60%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRONCHIAL HAEMORRHAGE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSPNOEA EXERTIONAL			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY OEDEMA			

subjects affected / exposed	0 / 334 (0.00%)	2 / 332 (0.60%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HAEMOPTYSIS			
subjects affected / exposed	2 / 334 (0.60%)	6 / 332 (1.81%)	5 / 334 (1.50%)
occurrences causally related to treatment / all	0 / 2	1 / 8	0 / 5
deaths causally related to treatment / all	0 / 0	1 / 3	0 / 1
ASPIRATION			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
ATELECTASIS			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
subjects affected / exposed	3 / 334 (0.90%)	2 / 332 (0.60%)	3 / 334 (0.90%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
subjects affected / exposed	3 / 334 (0.90%)	7 / 332 (2.11%)	3 / 334 (0.90%)
occurrences causally related to treatment / all	0 / 3	0 / 7	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 4	0 / 0
PNEUMOTHORAX SPONTANEOUS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LARYNGEAL HAEMORRHAGE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE			

subjects affected / exposed	3 / 334 (0.90%)	10 / 332 (3.01%)	7 / 334 (2.10%)
occurrences causally related to treatment / all	0 / 3	1 / 14	0 / 9
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 3
ACUTE RESPIRATORY FAILURE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RESPIRATORY FAILURE			
subjects affected / exposed	3 / 334 (0.90%)	3 / 332 (0.90%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 3	2 / 4	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Psychiatric disorders			
DEPRESSION			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HALLUCINATION			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONFUSIONAL STATE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COMPLETED SUICIDE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
SUICIDAL IDEATION			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MENTAL STATUS CHANGES			

subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
DEVICE DISLOCATION			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
PLATELET COUNT DECREASED			
subjects affected / exposed	2 / 334 (0.60%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	1 / 2	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUTROPHIL COUNT DECREASED			
subjects affected / exposed	1 / 334 (0.30%)	3 / 332 (0.90%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	1 / 1	3 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BLOOD CREATININE INCREASED			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LIVER FUNCTION TEST ABNORMAL			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BLOOD LACTIC ACID INCREASED			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GENERAL PHYSICAL CONDITION ABNORMAL			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

BLOOD BILIRUBIN INCREASED			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
WEIGHT DECREASED			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
CHEST INJURY			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUBDURAL HAEMATOMA			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RADIATION OESOPHAGITIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RADIATION PNEUMONITIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFUSION RELATED REACTION			
subjects affected / exposed	0 / 334 (0.00%)	2 / 332 (0.60%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERIORBITAL HAEMATOMA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

FEMORAL NECK FRACTURE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEMUR FRACTURE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIP FRACTURE			
subjects affected / exposed	0 / 334 (0.00%)	2 / 332 (0.60%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
THORACIC VERTEBRAL FRACTURE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TOXICITY TO VARIOUS AGENTS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HUMERUS FRACTURE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RIB FRACTURE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKIN LACERATION			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ALCOHOL POISONING			

subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FALL			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
TRACHEO-OESOPHAGEAL FISTULA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
SINUS TACHYCARDIA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANGINA UNSTABLE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TACHYCARDIA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERICARDIAL EFFUSION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	4 / 334 (1.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRADYCARDIA			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

ARRHYTHMIA			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ATRIAL THROMBOSIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ATRIAL FLUTTER			
subjects affected / exposed	1 / 334 (0.30%)	5 / 332 (1.51%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	1 / 1	3 / 5	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
CARDIAC FAILURE ACUTE			
subjects affected / exposed	2 / 334 (0.60%)	2 / 332 (0.60%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 2	1 / 1	0 / 0
ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	1 / 334 (0.30%)	2 / 332 (0.60%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
CARDIO-RESPIRATORY ARREST			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
CORONARY ARTERY STENOSIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC ARREST			
subjects affected / exposed	0 / 334 (0.00%)	2 / 332 (0.60%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
ATRIAL FIBRILLATION			

subjects affected / exposed	3 / 334 (0.90%)	6 / 332 (1.81%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 3	2 / 6	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LEFT VENTRICULAR DYSFUNCTION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC TAMPONADE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
CARDIAC FAILURE			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nervous system disorders			
BRAIN OEDEMA			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPINAL CORD COMPRESSION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEMIPLEGIA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CEREBRAL ISCHAEMIA			

subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TRANSIENT ISCHAEMIC ATTACK			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEPRESSED LEVEL OF CONSCIOUSNESS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PARAESTHESIA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GUILLAIN-BARRE SYNDROME			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
DIZZINESS			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MOTOR DYSFUNCTION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPOTONIA			

subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MYXOEDEMA COMA			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEIZURE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EMBOLIC STROKE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EPILEPSY			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERAESTHESIA			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ISCHAEMIC STROKE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CEREBROVASCULAR ACCIDENT			
subjects affected / exposed	1 / 334 (0.30%)	4 / 332 (1.20%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Blood and lymphatic system disorders			
HAEMOLYSIS			

subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUTROPENIA			
subjects affected / exposed	3 / 334 (0.90%)	2 / 332 (0.60%)	3 / 334 (0.90%)
occurrences causally related to treatment / all	2 / 3	2 / 2	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAEMIA			
subjects affected / exposed	3 / 334 (0.90%)	6 / 332 (1.81%)	7 / 334 (2.10%)
occurrences causally related to treatment / all	2 / 3	5 / 6	6 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEBRILE NEUTROPENIA			
subjects affected / exposed	5 / 334 (1.50%)	16 / 332 (4.82%)	13 / 334 (3.89%)
occurrences causally related to treatment / all	5 / 5	15 / 16	15 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOCYTOPENIA			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	1 / 1	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PANCYTOPENIA			
subjects affected / exposed	2 / 334 (0.60%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
RETINAL DETACHMENT			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
GASTROINTESTINAL TOXICITY			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONSTIPATION			

subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOMITING			
subjects affected / exposed	1 / 334 (0.30%)	3 / 332 (0.90%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 1	2 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTRITIS			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAL HAEMORRHAGE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UPPER GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INTESTINAL PERFORATION			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLITIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	3 / 334 (0.90%)
occurrences causally related to treatment / all	0 / 0	1 / 1	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIARRHOEA			

subjects affected / exposed	4 / 334 (1.20%)	3 / 332 (0.90%)	6 / 334 (1.80%)
occurrences causally related to treatment / all	4 / 5	4 / 4	4 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PANCREATITIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DUODENAL PERFORATION			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	2 / 334 (0.60%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
OESOPHAGITIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSPHAGIA			
subjects affected / exposed	0 / 334 (0.00%)	2 / 332 (0.60%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROINTESTINAL PERFORATION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTRIC ULCER			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN UPPER			

subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PANCREATITIS CHRONIC			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ENTEROCOLITIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
INGUINAL HERNIA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROINTESTINAL NECROSIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	1 / 1	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 1	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LARGE INTESTINE PERFORATION			

subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hepatobiliary disorders			
HEPATIC FUNCTION ABNORMAL			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
IMMUNE-MEDIATED HEPATITIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BILE DUCT STONE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DRUG-INDUCED LIVER INJURY			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLECYSTITIS ACUTE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEPATITIS			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEPATITIS TOXIC			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
AUTOIMMUNE HEPATITIS			

subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHOLECYSTITIS			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	1 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
ERYTHEMA MULTIFORME			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RASH			
subjects affected / exposed	0 / 334 (0.00%)	2 / 332 (0.60%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DERMATITIS ACNEIFORM			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	1 / 334 (0.30%)	2 / 332 (0.60%)	4 / 334 (1.20%)
occurrences causally related to treatment / all	0 / 1	2 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYDRONEPHROSIS			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY RETENTION			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

HYPOPITUITARISM			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ADRENAL INSUFFICIENCY			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTHYROIDISM			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
FLANK PAIN			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PATHOLOGICAL FRACTURE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POLYMYOSITIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POLYARTHRITIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

BACK PAIN			
subjects affected / exposed	0 / 334 (0.00%)	5 / 332 (1.51%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OSTEONECROSIS OF JAW			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OSTEONECROSIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ARTHRALGIA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
ABDOMINAL SEPSIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BRONCHITIS			
subjects affected / exposed	1 / 334 (0.30%)	6 / 332 (1.81%)	3 / 334 (0.90%)
occurrences causally related to treatment / all	0 / 1	2 / 6	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PSEUDOMONAL SEPSIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUNG ABSCESS			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL INFECTION			

subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLONIC ABSCESS			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFLUENZA			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
GASTROENTERITIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	3 / 334 (0.90%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA STAPHYLOCOCCAL			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA HAEMOPHILUS			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEPATITIS B			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MENINGITIS			

subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OSTEOMYELITIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BACTERAEemia			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
STOMATOCOCCAL INFECTION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
APPENDICITIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA STREPTOCOCCAL			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFECTION			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY SEPSIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VASCULAR DEVICE INFECTION			

subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
subjects affected / exposed	3 / 334 (0.90%)	1 / 332 (0.30%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL INFECTION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CLOSTRIDIUM DIFFICILE INFECTION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ENTEROCOLITIS INFECTIOUS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SINUSITIS			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION STAPHYLOCOCCAL			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA BACTERIAL			

subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UROSEPSIS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			
subjects affected / exposed	6 / 334 (1.80%)	10 / 332 (3.01%)	5 / 334 (1.50%)
occurrences causally related to treatment / all	2 / 6	2 / 11	1 / 5
deaths causally related to treatment / all	0 / 2	1 / 3	0 / 2
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
subjects affected / exposed	21 / 334 (6.29%)	30 / 332 (9.04%)	33 / 334 (9.88%)
occurrences causally related to treatment / all	9 / 21	7 / 32	6 / 37
deaths causally related to treatment / all	1 / 1	2 / 4	2 / 6
INFECTED DERMAL CYST			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RESPIRATORY TRACT INFECTION			
subjects affected / exposed	3 / 334 (0.90%)	2 / 332 (0.60%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 3	1 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CELLULITIS			
subjects affected / exposed	1 / 334 (0.30%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHRONIC HEPATITIS C			

subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPTIC SHOCK			
subjects affected / exposed	1 / 334 (0.30%)	1 / 332 (0.30%)	3 / 334 (0.90%)
occurrences causally related to treatment / all	1 / 1	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	1 / 2
ENDOCARDITIS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
HYPONATRAEMIA			
subjects affected / exposed	3 / 334 (0.90%)	1 / 332 (0.30%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	1 / 3	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERCALCAEMIA			
subjects affected / exposed	2 / 334 (0.60%)	2 / 332 (0.60%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 2	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FAILURE TO THRIVE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERGLYCAEMIA			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEHYDRATION			

subjects affected / exposed	2 / 334 (0.60%)	4 / 332 (1.20%)	3 / 334 (0.90%)
occurrences causally related to treatment / all	2 / 2	4 / 4	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPOKALAEMIA			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPOMAGNESAEMIA			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DECREASED APPETITE			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERKALAEMIA			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPOCALCAEMIA			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	2 / 334 (0.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIABETES MELLITUS			
subjects affected / exposed	0 / 334 (0.00%)	1 / 332 (0.30%)	0 / 334 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TYPE 2 DIABETES MELLITUS			
subjects affected / exposed	0 / 334 (0.00%)	0 / 332 (0.00%)	1 / 334 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Arm C: Nab-Paclitaxel + Carboplatin	Arm A: Atezolizumab + Paclitaxel + Carboplatin	Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Total subjects affected by non-serious adverse events			
subjects affected / exposed	315 / 334 (94.31%)	315 / 332 (94.88%)	325 / 334 (97.31%)
Vascular disorders			
HYPOTENSION			
subjects affected / exposed	12 / 334 (3.59%)	22 / 332 (6.63%)	18 / 334 (5.39%)
occurrences (all)	18	25	25
General disorders and administration site conditions			
PYREXIA			
subjects affected / exposed	34 / 334 (10.18%)	46 / 332 (13.86%)	45 / 334 (13.47%)
occurrences (all)	42	68	66
FATIGUE			
subjects affected / exposed	88 / 334 (26.35%)	97 / 332 (29.22%)	107 / 334 (32.04%)
occurrences (all)	101	112	137
ASTHENIA			
subjects affected / exposed	66 / 334 (19.76%)	77 / 332 (23.19%)	58 / 334 (17.37%)
occurrences (all)	85	101	81
CHEST PAIN			
subjects affected / exposed	18 / 334 (5.39%)	28 / 332 (8.43%)	25 / 334 (7.49%)
occurrences (all)	19	35	31
MUCOSAL INFLAMMATION			
subjects affected / exposed	9 / 334 (2.69%)	17 / 332 (5.12%)	16 / 334 (4.79%)
occurrences (all)	11	17	23
MALAISE			
subjects affected / exposed	16 / 334 (4.79%)	10 / 332 (3.01%)	18 / 334 (5.39%)
occurrences (all)	24	14	26
OEDEMA PERIPHERAL			
subjects affected / exposed	22 / 334 (6.59%)	23 / 332 (6.93%)	25 / 334 (7.49%)
occurrences (all)	25	28	32
Respiratory, thoracic and mediastinal disorders			
DYSPHONIA			

subjects affected / exposed	11 / 334 (3.29%)	17 / 332 (5.12%)	19 / 334 (5.69%)
occurrences (all)	11	17	20
DYSPNOEA			
subjects affected / exposed	57 / 334 (17.07%)	64 / 332 (19.28%)	68 / 334 (20.36%)
occurrences (all)	65	75	100
EPISTAXIS			
subjects affected / exposed	37 / 334 (11.08%)	8 / 332 (2.41%)	34 / 334 (10.18%)
occurrences (all)	43	9	44
HAEMOPTYSIS			
subjects affected / exposed	18 / 334 (5.39%)	18 / 332 (5.42%)	19 / 334 (5.69%)
occurrences (all)	27	20	29
COUGH			
subjects affected / exposed	51 / 334 (15.27%)	62 / 332 (18.67%)	65 / 334 (19.46%)
occurrences (all)	61	69	85
Psychiatric disorders			
INSOMNIA			
subjects affected / exposed	27 / 334 (8.08%)	29 / 332 (8.73%)	30 / 334 (8.98%)
occurrences (all)	28	32	34
ANXIETY			
subjects affected / exposed	10 / 334 (2.99%)	17 / 332 (5.12%)	9 / 334 (2.69%)
occurrences (all)	10	17	10
Investigations			
PLATELET COUNT DECREASED			
subjects affected / exposed	59 / 334 (17.66%)	40 / 332 (12.05%)	59 / 334 (17.66%)
occurrences (all)	110	64	128
NEUTROPHIL COUNT DECREASED			
subjects affected / exposed	65 / 334 (19.46%)	18 / 332 (5.42%)	60 / 334 (17.96%)
occurrences (all)	144	25	132
BLOOD CREATININE INCREASED			
subjects affected / exposed	3 / 334 (0.90%)	16 / 332 (4.82%)	25 / 334 (7.49%)
occurrences (all)	4	16	28
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	8 / 334 (2.40%)	25 / 332 (7.53%)	17 / 334 (5.09%)
occurrences (all)	8	33	18
ASPARTATE AMINOTRANSFERASE INCREASED			

subjects affected / exposed occurrences (all)	17 / 334 (5.09%) 27	31 / 332 (9.34%) 56	34 / 334 (10.18%) 64
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed occurrences (all)	18 / 334 (5.39%) 23	34 / 332 (10.24%) 56	40 / 334 (11.98%) 64
WHITE BLOOD CELL COUNT DECREASED			
subjects affected / exposed occurrences (all)	36 / 334 (10.78%) 68	12 / 332 (3.61%) 19	32 / 334 (9.58%) 64
WEIGHT DECREASED			
subjects affected / exposed occurrences (all)	14 / 334 (4.19%) 14	21 / 332 (6.33%) 22	32 / 334 (9.58%) 38
Nervous system disorders			
PERIPHERAL SENSORY NEUROPATHY			
subjects affected / exposed occurrences (all)	30 / 334 (8.98%) 35	55 / 332 (16.57%) 68	48 / 334 (14.37%) 54
DYSGEUSIA			
subjects affected / exposed occurrences (all)	22 / 334 (6.59%) 22	15 / 332 (4.52%) 15	26 / 334 (7.78%) 30
HEADACHE			
subjects affected / exposed occurrences (all)	18 / 334 (5.39%) 26	38 / 332 (11.45%) 44	33 / 334 (9.88%) 40
PARAESTHESIA			
subjects affected / exposed occurrences (all)	15 / 334 (4.49%) 16	28 / 332 (8.43%) 33	16 / 334 (4.79%) 17
DIZZINESS			
subjects affected / exposed occurrences (all)	33 / 334 (9.88%) 42	33 / 332 (9.94%) 35	32 / 334 (9.58%) 38
NEUROPATHY PERIPHERAL			
subjects affected / exposed occurrences (all)	36 / 334 (10.78%) 39	66 / 332 (19.88%) 73	34 / 334 (10.18%) 39
Blood and lymphatic system disorders			
NEUTROPENIA			
subjects affected / exposed occurrences (all)	124 / 334 (37.13%) 214	43 / 332 (12.95%) 61	121 / 334 (36.23%) 261
ANAEMIA			

subjects affected / exposed occurrences (all)	193 / 334 (57.78%) 244	131 / 332 (39.46%) 153	188 / 334 (56.29%) 257
THROMBOCYTOPENIA subjects affected / exposed occurrences (all)	92 / 334 (27.54%) 171	46 / 332 (13.86%) 66	91 / 334 (27.25%) 163
LEUKOPENIA subjects affected / exposed occurrences (all)	34 / 334 (10.18%) 54	8 / 332 (2.41%) 8	42 / 334 (12.57%) 86
Gastrointestinal disorders			
CONSTIPATION subjects affected / exposed occurrences (all)	73 / 334 (21.86%) 85	75 / 332 (22.59%) 94	101 / 334 (30.24%) 126
VOMITING subjects affected / exposed occurrences (all)	48 / 334 (14.37%) 59	50 / 332 (15.06%) 64	67 / 334 (20.06%) 88
DIARRHOEA subjects affected / exposed occurrences (all)	77 / 334 (23.05%) 107	94 / 332 (28.31%) 116	92 / 334 (27.54%) 135
NAUSEA subjects affected / exposed occurrences (all)	97 / 334 (29.04%) 137	94 / 332 (28.31%) 139	131 / 334 (39.22%) 206
STOMATITIS subjects affected / exposed occurrences (all)	15 / 334 (4.49%) 17	20 / 332 (6.02%) 24	22 / 334 (6.59%) 27
ABDOMINAL PAIN subjects affected / exposed occurrences (all)	8 / 334 (2.40%) 8	18 / 332 (5.42%) 20	9 / 334 (2.69%) 13
ABDOMINAL PAIN UPPER subjects affected / exposed occurrences (all)	17 / 334 (5.09%) 17	12 / 332 (3.61%) 15	13 / 334 (3.89%) 17
Skin and subcutaneous tissue disorders			
RASH subjects affected / exposed occurrences (all)	18 / 334 (5.39%) 19	44 / 332 (13.25%) 57	47 / 334 (14.07%) 55
PRURITUS			

subjects affected / exposed occurrences (all)	13 / 334 (3.89%) 14	32 / 332 (9.64%) 42	24 / 334 (7.19%) 36
ALOPECIA subjects affected / exposed occurrences (all)	102 / 334 (30.54%) 103	130 / 332 (39.16%) 134	114 / 334 (34.13%) 114
DRY SKIN subjects affected / exposed occurrences (all)	5 / 334 (1.50%) 5	13 / 332 (3.92%) 14	19 / 334 (5.69%) 21
Endocrine disorders HYPOTHYROIDISM subjects affected / exposed occurrences (all)	2 / 334 (0.60%) 2	27 / 332 (8.13%) 30	34 / 334 (10.18%) 40
Musculoskeletal and connective tissue disorders BACK PAIN subjects affected / exposed occurrences (all)	16 / 334 (4.79%) 17	33 / 332 (9.94%) 38	35 / 334 (10.48%) 40
BONE PAIN subjects affected / exposed occurrences (all)	3 / 334 (0.90%) 3	23 / 332 (6.93%) 36	11 / 334 (3.29%) 14
ARTHRALGIA subjects affected / exposed occurrences (all)	33 / 334 (9.88%) 37	78 / 332 (23.49%) 107	53 / 334 (15.87%) 78
MYALGIA subjects affected / exposed occurrences (all)	19 / 334 (5.69%) 24	44 / 332 (13.25%) 63	22 / 334 (6.59%) 23
PAIN IN EXTREMITY subjects affected / exposed occurrences (all)	17 / 334 (5.09%) 17	35 / 332 (10.54%) 48	32 / 334 (9.58%) 35
Infections and infestations RESPIRATORY TRACT INFECTION subjects affected / exposed occurrences (all)	6 / 334 (1.80%) 6	25 / 332 (7.53%) 38	10 / 334 (2.99%) 17
NASOPHARYNGITIS subjects affected / exposed occurrences (all)	9 / 334 (2.69%) 11	23 / 332 (6.93%) 35	21 / 334 (6.29%) 28
UPPER RESPIRATORY TRACT INFECTION			

subjects affected / exposed occurrences (all)	6 / 334 (1.80%) 6	18 / 332 (5.42%) 30	18 / 334 (5.39%) 24
PNEUMONIA subjects affected / exposed occurrences (all)	16 / 334 (4.79%) 19	23 / 332 (6.93%) 28	29 / 334 (8.68%) 30
URINARY TRACT INFECTION subjects affected / exposed occurrences (all)	16 / 334 (4.79%) 20	18 / 332 (5.42%) 27	26 / 334 (7.78%) 45
Metabolism and nutrition disorders			
HYPONATRAEMIA subjects affected / exposed occurrences (all)	5 / 334 (1.50%) 5	17 / 332 (5.12%) 22	11 / 334 (3.29%) 17
HYPERGLYCAEMIA subjects affected / exposed occurrences (all)	17 / 334 (5.09%) 19	25 / 332 (7.53%) 28	18 / 334 (5.39%) 29
DEHYDRATION subjects affected / exposed occurrences (all)	11 / 334 (3.29%) 15	20 / 332 (6.02%) 30	23 / 334 (6.89%) 33
HYPOKALAEMIA subjects affected / exposed occurrences (all)	23 / 334 (6.89%) 28	24 / 332 (7.23%) 30	30 / 334 (8.98%) 39
HYPOMAGNESAEMIA subjects affected / exposed occurrences (all)	38 / 334 (11.38%) 56	35 / 332 (10.54%) 47	54 / 334 (16.17%) 91
DECREASED APPETITE subjects affected / exposed occurrences (all)	84 / 334 (25.15%) 98	93 / 332 (28.01%) 109	82 / 334 (24.55%) 110

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 March 2015	Protocol was amended to clarify the inclusion criterion on contraception. In addition, reporting for serious adverse events and adverse events of special interest has been extended to 90 days after last dose of study treatment or until initiation of a new anticancer therapy, whichever occurs first.
14 August 2015	Protocol was amended to update the contraception requirements in the inclusion and exclusion criteria and the pregnancy-reporting information to be consistent with safety information for nab-paclitaxel. The study inclusion criteria have been modified, on the basis of an expanding safety database, to allow for patients with treated, asymptomatic cerebellar metastases to be enrolled provided specific criteria are met. The exclusion criteria for history of autoimmune disease has been broadened, on the basis of an expanding safety database, to allow for patients with eczema, psoriasis, or lichen simplex chronicus of vitiligo with dermatologic manifestations only to be permitted provided that they meet the specific conditions. The study exclusion criteria regarding treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug (whichever is shorter) prior to randomization has been modified to 4 weeks prior to randomization for consistency with more recent atezolizumab protocols. The exclusion criterion specifying that patients with a history of allergic reaction to intravenous contrast that requires steroid pretreatment should have baseline and subsequent tumor assessments performed via magnetic resonance imaging (MRI) has been removed.
11 November 2015	Protocol was amended to clarify that a wash-out period of at least 4 weeks or five half-lives, whichever is longer, of any systemic immunomodulatory agent is required prior to enrollment.
15 June 2016	Protocol was amended to add a co-primary endpoint of overall survival (OS) to the progression-free survival (PFS) primary endpoint. A secondary efficacy objective and outcome measure was added to evaluate the efficacy of atezolizumab + carboplatin + nab-paclitaxel compared with carboplatin + nab-paclitaxel as measured by investigator-assessed time to response (TTR) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for both the ITT and PD-L1–selected populations. The inclusion criteria was modified to specify that patients who have received prior radiotherapy with curative intent must be treatment-free for at least a 6-month interval prior to randomization. Based on the half-life of atezolizumab of 27 days, the language regarding length of female patient contraception and follow-up of pregnancy reporting has been revised from 90 days to 5 months. The contraception requirements for male patients and pregnancy-reporting requirements for female partners of male patients who receive atezolizumab have been updated on the basis of the safety information for atezolizumab.
01 March 2017	Protocol was amended to include changes in the primary analysis populations for the co-primary endpoints of progression-free survival (PFS) and overall survival (OS). OS will be analyzed in the intent-to-treat (ITT) population, PFS will be analyzed in the ITT population with a defined level of expression of a PD-L1 and T-effector gene signature in tumor tissue as determined by an RNA-based assay.
24 October 2018	Protocol was amended to include correction to the end of study definition. This correction ensures that the study continues until last patient, last visit or until the Sponsor terminates the study. Inclusion criterion has been modified to address female contraception to specify when women must refrain from donating eggs.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported